Lexaria Bioscience (LEXX) S-1 3 Jun 20 IPO registration Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Feb. 29, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	Lexaria Bioscience Corp.
Entity Central Index Key	0001348362
Entity Filer Category	Accelerated Filer
Document Type	S-1
Amendment Flag	false
Entity Small Business	true
Entity Emerging Growth Company	false

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($)	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Current
Cash and cash equivalents	$ 739,985	$ 1,285,147	$ 1,727,184
Marketable securities (Note 19)	23,623	64,214	10,151
Accounts receivable (Note 7)	227,266	273,145	265,751
Inventory (Note 8)	124,412	127,396	87,233
Prepaid expenses and deposit (Note 18)	64,757	68,927	193,732
Total Current Assets	1,180,043	1,818,829	2,284,051
Capital assets, net
Intellectual property (Note 9)	267,995	265,127	146,538
Property & Equipment (Note 10)	538,188	591,263	1,237
Total Noncurrent Assets	806,183	856,390	147,775
TOTAL ASSETS	1,986,226	2,675,219	2,431,826
Current
Accounts payable and accrued liabilities (Note 11)	61,690	136,411	35,785
Due to a related party (Note 15)	1,600	48,096	7,855
Total Current Liabilities	63,290	184,507	43,640
TOTAL LIABILITIES	63,290	184,507	43,640
STOCKHOLDERS' EQUITY
Share Capital (Note 12) Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Issued and outstanding: 80,720,879 common shares at February 29, 2020, 78,787,134 common shares at August 31, 2019 and 75,533,471 common shares at August 31, 2018	80,721	78,787	75,533
Additional paid-in capital (Note 12, 13)	27,524,998	26,172,453	22,095,682
Accumulated Other Comprehensive Income			(14,247)
Deficit	(25,725,859)	(23,868,202)	(19,768,782)
Equity attributable to shareholders of the Company	1,879,860	2,383,038	2,388,186
Non-Controlling Interest	43,076	107,674
Total Stockholders' Equity	1,922,936	2,490,712	2,388,186
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 1,986,226	$ 2,675,219	$ 2,431,826

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Statement of Financial Position [Abstract]
Common stock, shares authorized	220,000,000	220,000,000	220,000,000
Common stock, par value per share (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares, issued	80,720,879	78,787,134	75,533,471
Common stock, shares, outstanding	80,720,879	78,787,134	75,533,471

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019	Aug. 31, 2019	Aug. 31, 2018
Income Statement [Abstract]
Revenue (Note 14)	$ 107,299	$ 15,349	$ 169,381	$ 37,558	$ 222,610	$ 433,287
Cost of Goods Sold	58,106	2,690	65,959	4,848	22,893	25,185
Gross profit	49,193	12,659	103,422	32,710	199,717	408,102
Expenses
Accounting and audit	7,493	17,495	26,529	27,067	77,388	85,553
Depreciation and amortization (Note 9, 10)	28,282	10,086	55,794	11,689	60,550	2,307
Advertising and promotions	34,717	113,229	80,985	285,142	515,360	489,058
Bad Debt					75,000
Consulting (Notes 12, 13, 15)	521,228	603,427	1,005,024	846,418	1,444,735	5,332,398
Investor relation	3,762		21,277		203,893	188
Legal and professional	88,002	257,381	140,357	354,033	670,863	289,062
Office and miscellaneous	65,100	52,258	139,127	125,160	297,209	217,655
Research and development	186,557	66,083	294,020	163,056	555,730	492,864
Travel	21,759	20,293	43,612	39,499	100,587	99,236
Wages and salaries	90,768	25,627	178,361	25,627	333,199
Gain on disposal of assets						(3,998)
Unrealized Loss on marketable securities (Note 19)	(983)	(109)	40,591	9,521	16,434
Inventory writeoff (Note 8)					7,182	12,966
Total Operating Expenses	1,046,685	1,165,770	2,025,677	1,887,212	4,358,130	7,017,289
Net loss and comprehensive loss for the period	(997,492)	(1,153,111)	(1,922,255)	(1,854,502)	(4,158,413)	(6,609,187)
Net loss and comprehensive loss attributable to:
Common shareholders	(950,344)	(1,147,976)	(1,857,657)	(1,849,367)	(4,099,420)	(6,598,843)
Non-controlling interest	$ (47,148)	$ (5,135)	$ (64,598)	$ (5,135)	$ (58,993)	$ (10,344)
Basic and diluted loss per share (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.09)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	79,890,378	77,101,038	79,890,378	76,079,651	77,792,263	70,960,416

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	6 Months Ended		12 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Aug. 31, 2019	Aug. 31, 2018
Cash flows used in operating activities
Net loss and comprehensive loss	$ (1,922,255)	$ (1,854,502)	$ (4,158,413)	$ (6,609,187)
Adjustments to reconcile net loss to net cash Used in operating activities:
Stock based compensation	456,707	64,044	626,692	2,602,239
Depreciation and amortization	55,794	11,689	60,550	2,307
Inventory write-off (Note 7)			7,182	12,966
Bad Debt Expense			75,000
Unrealized loss on marketable securities	40,591	9,521	16,434
Unrealized foreign exchange				602
Common shares issued for services		131,000	234,500	781,056
Warrants issued for services	70,752		52,817	1,063,270
Change in working capital
Accounts receivable	45,879	(9,604)	(138,644)	(245,458)
Inventory	3,108	(20,785)	(47,345)	(33,025)
Prepaid expenses and deposits	4,170	44,629	124,805	(44,041)
Accounts payable and accrued liabilities	(74,721)	458,673	100,626	3,210
Due to related parties	(46,496)	(2,234)	40,241	(34,835)
Deferred revenue				(17,083)
Net cash used in operating activities	(1,366,471)	(1,167,569)	(3,005,555)	(2,517,979)
Cash flows used in investing activities
Investment from Altria		1,000,000
Investment in Poviva				(70,000)
Intellectual property	(5,711)	(55,743)	(122,982)	(85,399)
Property & Equipment		(441,150)	(646,183)
Net cash used in investing activities	(5,711)	503,107	(769,165)	(155,399)
Cash flows from financing activities
Investment from NCI			1,000,000
Proceeds from issuance of equity	827,020	2,030,489	2,332,683	1,867,224
Net cash from financing activities	827,020	2,030,489	3,332,683	1,867,224
Increase(Decrease) in cash and cash equivalents	(545,162)	1,366,027	(442,037)	(806,153)
Cash and cash equivalents, beginning of year	1,285,147	1,727,184	1,727,184	2,533,337
Cash and cash equivalents, end of year	739,985	3,093,211	1,285,147	1,727,184
Supplemental information of cash flows:
Subscription Funds Payable		31,500
Income taxes paid in cash	$ 957	$ 13,869	13,919
Common shares issued to settle AP				12,000
Reclassification of NCI to additional paid in capital on acquisition			$ 833,333	$ 318,820

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	DEFICIT	NCI	AOCI	Total
Balance at Aug. 31, 2017	$ 67,976
Balance (Shares) at Aug. 31, 2017	67,975,761	16,108,270	(13,169,939)	(238,476)	0	2,767,831
Shares issued for services	$ 648	$ 780,408				$ 781,056
Shares issued for services (Shares)	647,690
Stock based compensation		2,602,239				2,602,239
Warrants issued for services		1,063,270				1,063,270
Exercise of stock options	$ 546	93,156				$ 93,702
Exercise of stock options (in shares)	545,875					545,875
Exercise of warrants	$ 6,363	1,767,159				$ 1,773,522
Exercise of warrants (in shares)	6,364,145
Net loss						(6,598,843)
Net loss			$ (6,598,843)	$ (10,344)		(6,609,187)
Net loss non-controlling interest						(10,344)
Non-controlling Interest		(318,820)		$ 248,820		(70,000)
Other comprehensive income (loss)					$ (14,247)	(14,247)
Balance at Aug. 31, 2018	$ 75,533	$ 22,095,682	$ (19,768,782)		$ (14,247)	$ 2,388,186
Balance (Shares) at Aug. 31, 2018	75,533,471	22,095,682	19,768,782	0	14,247	2,388,186
Stock based compensation		$ 64,044				$ 64,044
Private Placement	$ 947	1,469,363				1,470,310
Private Placement (Shares)	947,150
Exercise of stock options	$ 330	32,670				33,000
Exercise of stock options (in shares)	330,000
Exercise of warrants	$ 310	145,570				145,880
Exercise of warrants (in shares)	309,800
Net loss			$ (701,391)			(701,391)
AOCI					$ 14,247	14,247
Balance at Nov. 30, 2018	$ 77,120	23,807,329	(20,470,173)			3,414,276
Balance (Shares) at Nov. 30, 2018	77,120,421
Balance at Aug. 31, 2018	$ 75,533	$ 22,095,682	$ (19,768,782)		$ (14,247)	$ 2,388,186
Balance (Shares) at Aug. 31, 2018	75,533,471	22,095,682	19,768,782	0	14,247	2,388,186
Net loss						$ (1,849,367)
Net loss						(1,854,502)
Net loss non-controlling interest						(5,135)
Balance at Feb. 28, 2019	$ 78,002	$ 24,318,746	$ (21,618,149)	$ 994,865		3,773,464
Balance (Shares) at Feb. 28, 2019	78,002,086
Balance at Aug. 31, 2018	$ 75,533	$ 22,095,682	$ (19,768,782)		$ (14,247)	$ 2,388,186
Balance (Shares) at Aug. 31, 2018	75,533,471	22,095,682	19,768,782	0	14,247	2,388,186
Shares issued for services	$ 250	$ 234,250				$ 234,500
Shares issued for services (Shares)	250,000
Stock based compensation		626,692				626,692
Private Placement	$ 947	1,469,363				1,470,310
Private Placement (Shares)	947,150
Warrants issued for services		52,817				52,817
Exercise of stock options	$ 430	65,820				$ 66,250
Exercise of stock options (in shares)	430,000					430,000
Exercise of warrants	$ 1,627	794,496				$ 796,123
Exercise of warrants (in shares)	1,626,513
Net loss			$ (4,099,420)			(4,099,420)
Net loss						(4,158,413)
Net loss non-controlling interest						(58,993)
Non-controlling Interest				$ (58,993)		(58,993)
Other comprehensive income (loss)					$ 14,247	14,247
Subsidiary Investment		833,333		166,667		1,000,000
Balance at Aug. 31, 2019	$ 78,787	$ 26,172,453	$ (23,868,202)	$ 107,674		$ 2,490,712
Balance (Shares) at Aug. 31, 2019	78,787,134	26,172,453	23,868,202	107,674	0	2,490,712
Balance at Nov. 30, 2018	$ 77,120	$ 23,807,329	$ (20,470,173)			$ 3,414,276
Balance (Shares) at Nov. 30, 2018	77,120,421
Shares issued for services	$ 100	130,900				131,000
Shares issued for services (Shares)	100,000
Exercise of stock options	$ 50	18,450				18,500
Exercise of stock options (in shares)	50,000
Exercise of warrants	$ 732	362,067				362,799
Exercise of warrants (in shares)	731,665
Net loss			(1,147,976)			(1,147,976)
Net loss						(1,153,111)
Net loss non-controlling interest				$ (5,135)		(5,135)
Non-controlling Interest				1,000,000		1,000,000
Balance at Feb. 28, 2019	$ 78,002	24,318,746	(21,618,149)	994,865		3,773,464
Balance (Shares) at Feb. 28, 2019	78,002,086
Stock based compensation		443,266				443,266
Warrants issued for services		52,817				52,817
Exercise of stock options	$ 50	14,700				14,750
Exercise of stock options (in shares)	50,000
Exercise of warrants	$ 385	228,058				228,444
Exercise of warrants (in shares)	385,048
Net loss			(1,171,805)			(1,171,805)
Net loss non-controlling interest				(16,131)		(16,131)
Non-controlling Interest		833,333		(833,333)
Balance at May. 31, 2019	$ 78,437	25,890,921	(22,789,954)	145,401		3,324,805
Balance (Shares) at May. 31, 2019	78,437,134
Shares issued for services	$ 150	103,350				103,500
Shares issued for services (Shares)	150,000
Stock based compensation		119,382				119,382
Exercise of warrants	$ 200	58,800				59,000
Exercise of warrants (in shares)	200,000
Net loss			(1,078,248)			(1,078,248)
Net loss non-controlling interest				(37,727)		(37,727)
Balance at Aug. 31, 2019	$ 78,787	$ 26,172,453	$ (23,868,202)	$ 107,674		$ 2,490,712
Balance (Shares) at Aug. 31, 2019	78,787,134	26,172,453	23,868,202	107,674	0	2,490,712
Stock based compensation		$ 162,414				$ 162,414
Private Placement	$ 1,824	814,196				816,020
Private Placement (Shares)	1,823,745
Warrants issued for services		70,752				70,752
Net loss			$ (907,313)			(907,313)
Non-controlling Interest				$ (17,450)		(17,450)
Balance at Nov. 30, 2019	$ 80,611	27,219,815	(24,775,515)	90,224		2,615,135
Balance (Shares) at Nov. 30, 2019	80,610,879
Balance at Aug. 31, 2019	$ 78,787	$ 26,172,453	$ (23,868,202)	$ 107,674		$ 2,490,712
Balance (Shares) at Aug. 31, 2019	78,787,134	26,172,453	23,868,202	107,674	0	2,490,712
Exercise of stock options						$ 11,000
Exercise of stock options (in shares)						110,000
Net loss						$ (1,857,657)
Net loss						(1,922,255)
Net loss non-controlling interest						(64,598)
Balance at Feb. 29, 2020	$ 80,721	$ 27,524,998	$ (25,725,859)	$ 43,076		1,922,936
Balance (Shares) at Feb. 29, 2020	80,720,879
Balance at Nov. 30, 2019	$ 80,611	27,219,815	(24,775,515)	90,224		2,615,135
Balance (Shares) at Nov. 30, 2019	80,610,879
Stock based compensation		294,293				294,293
Exercise of stock options	$ 110	10,890				11,000
Exercise of stock options (in shares)	110,000
Net loss			(950,344)			(950,344)
Net loss						(997,492)
Net loss non-controlling interest						(47,148)
Non-controlling Interest				(47,148)		(47,148)
Balance at Feb. 29, 2020	$ 80,721	$ 27,524,998	$ (25,725,859)	$ 43,076		$ 1,922,936
Balance (Shares) at Feb. 29, 2020	80,720,879

Organization, Business and Goin

Organization, Business and Going Concern	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Organization, Business And Going Concern [Abstract]
Organization, Business and Going Concern	1. Organization, Business and Going Concern Lexaria Bioscience Corp. (“Lexaria”, or the “Company”) was formed on December 9, 2004 under the laws of the State of Nevada. In March of 2014, the Company began its entry into the bioscience and alternative health and wellness business. In May 2016, the Company commenced out-licensing its patented DehydraTECH™ technology (the “Technology”) for improved delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company has its office in Kelowna, BC, Canada. The Company’s unaudited interim consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (US GAAP) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated annual financial statements and notes thereto included in our annual report filed on Form 10-K for the year ended August 31, 2019. The Company’s unaudited interim consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The recurring losses from operations and net capital deficiency raise substantial doubt about the Company’s ability to continue as a going concern. The Company requires additional funds or revenues to maintain its operations and developments. Management’s plans in this regard are to raise equity and debt financing as required, but there is no certainty that such financing will be available or that it will be available at acceptable terms. The outcome of these matters cannot be predicted at this time.	1. Organization, Business and Going Concern Lexaria Bioscience Corp. (“Lexaria”, or the “Company”) was formed on December 9, 2004 under the laws of the State of Nevada. In March of 2014, the Company began its entry into the bioscience and alternative health and wellness business and in May 2016, the Company commenced out-licensing its patented DehydraTECH™ technology (the “Technology”) for improved delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company has its office in Kelowna, BC, Canada. The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (US GAAP) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The recurring losses from operations and net capital deficiency raise substantial doubt about the Company’s ability to continue as a going concern. The Company requires additional funds to maintain its operations and developments. Management’s plans in this regard are to raise equity and debt financing as required, but there is no certainty that such financing will be available or that it will be available at acceptable terms. The outcome of these matters cannot be predicted at this time.

Business Risk and Liquidity

Business Risk and Liquidity	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Business Risk And Liquidity [Abstract]
Business Risk and Liquidity	2. Business Risk and Liquidity The Company is subject to several categories of risk associated with its operating activities. The production and sale of alternative health products is an emerging industry in which business practices are not yet standardized and are subject to frequent scrutiny and evaluation by federal, state, provincial, and municipal authorities, academics, and media outlets, among others. Although we intend to develop our businesses in accordance with best ethical practices, we may suffer negative publicity if we, our partners, contractors, or customers are found to have engaged in any environmentally insensitive practices or other business practices that are viewed as unethical. Our operations may require licenses and permits from various governmental authorities. We believe that we will be able to continue to obtain all necessary licenses and permits under applicable laws and regulations for our operations and believe we will be able to comply in all material respects with the terms of such licenses and permits. However, such licenses and permits are subject to change in various circumstances. There can be no guarantee that we will be able to obtain or maintain all necessary licenses and permits, and failing to obtain or retain required licenses could have a materially adverse effect on the Company. Lexaria and its subsidiaries are not involved directly or indirectly in the cultivation, processing, distribution, or utilization of cannabis or cannabis derived components. All of Lexaria’s consumer products utilize legally sourced hemp and hemp components in their production. Lexaria does have an ancillary involvement risk via out-licensing of its patented technology to licensees that choose to utilize its Technology to manufacture products that contain locally or state approved but federally regulated and controlled contents. There can be no guarantee that changes in the regulatory framework and environment will not occur and such changes could have a materially adverse effect on the Company. Lexaria and its subsidiaries are not involved directly or indirectly in the production or sale of any products containing nicotine. Products containing nicotine have historically been involved in litigation in the USA. Lexaria’s corporate licensee may introduce products containing nicotine that utilize Lexaria’s Technology to the US consumer market, which could therefore introduce third-party risks to Lexaria.	2. Business Risk and Liquidity The Company is subject to several categories of risk associated with its operating activities. The production and sale of alternative health products is an emerging industry in which business practices are not yet standardized and are subject to frequent scrutiny and evaluation by federal, state, provincial, and municipal authorities, academics, and media outlets, among others. Although we intend to develop our businesses in accordance with best ethical practices, we may suffer negative publicity if we, our partners, contractors, or customers are found to have engaged in any environmentally insensitive practices or other business practices that are viewed as unethical. Our operations may require licenses and permits from various governmental authorities. We believe that we will be able to obtain all necessary licenses and permits under applicable laws and regulations for our operations and believe we will be able to comply in all material respects with the terms of such licenses and permits. However, such licenses and permits are subject to change in various circumstances. There can be no guarantee that we will be able to obtain or maintain all necessary licenses and permits, and failing to obtain or retain required licenses could have a materially adverse effect on the Company. Lexaria and its subsidiaries are not involved directly or indirectly in the cultivation, processing, distribution, or utilization of Cannabis or Cannabis derived components. All of Lexaria’s consumer products utilize legally sourced Hemp and Hemp components in their production. Lexaria does have an ancillary involvement risk via out-licensing of its patented Technology to licensees that choose to utilize its Technology to manufacture products that contain locally or state approved but federally regulated and controlled contents. There can be no guarantee that changes in the regulatory framework and environment will not occur and such changes could have a materially adverse effect on the Company. Lexaria and its subsidiaries are not involved directly or indirectly in the production or sale of any products containing nicotine. Products containing nicotine have historically been involved in litigation in the USA. Lexaria’s corporate licensee may introduce products containing nicotine that utilize Lexaria’s technology to the US consumer market, which could therefore introduce third-party risks to Lexaria.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies The significant accounting policies of the Company are consistent with those of our audited financial statements on Form 10-K for the year ended August 31, 2019.	3. Significant Accounting Policies a) Accounting Principles These consolidated financial statements have been prepared in conformity with generally accepted accounting principles of the United States of America. All amounts, unless otherwise stated, are in United States dollars. b) Revenue Recognition Product Revenue Revenue from the sale of products is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable, and collectability is reasonably assured, which typically occurs upon shipment. The Company reports its sales net of the amount of actual sales returns. Sales tax collected from customers is excluded from net sales. Licensing Revenue from Intellectual Property We recognize revenue for License fees at a point in time following the transfer of our intellectual property, our patented lipid nutrient infusion technology DehydraTECH™ for infusing Active Pharmaceutical Ingredients, to the licensee, which typically occurs on delivery of documentation. Usage Fees from Intellectual Property We recognize revenue for Usage fees when usage of our DehydraTECH intellectual property occurs by licensees infusing an Active Pharmaceutical Ingredient into one or more of their product lines for sale. c) Inventory and Cost of Sales The Company’s inventory consists of finished goods, work in progress, and raw materials. In all classes, inventory is valued at the lower of cost or market. Cost is determined on a first-in, first-out basis. Cost of sales includes all expenditures incurred in bringing the goods to the point of sale. Inventory costs and costs of sales include direct costs of the raw material, inbound freight charges, warehousing costs, handling costs (receiving and purchasing) and utilities and overhead expenses related to the Company’s manufacturing and processing facilities. d) Cash and Cash Equivalents Cash equivalents comprise certain highly liquid instruments with a maturity of three months or less when purchased. As of August 31, 2019, and August 31, 2018, the Company held cash only. e) Equipment Equipment is stated at cost less accumulated depreciation and impairment, and depreciated using the straight-line method over their useful lives or by units of production. f) Patents Capitalized patent costs represent legal costs incurred to establish patents. When patents reach a mature stage, any associated legal costs are comprised mostly of maintenance fees and are expensed as incurred. Capitalized patent costs are amortized on a straight-line basis over the remaining life of the patent. The Company was granted its first patent on October 25, 2016, with a legal life of 20 years. Additional patent information is in Note 9. g) Stock-Based Compensation The Company accounts for its stock-based compensation awards in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized as expenses in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. Stock-based payments issued to non-employees are recorded at their fair values and are periodically revalued as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted to non-employees, the Company recognizes stock-based compensation expense on vesting. h) Loss Per Share The Company applies the guidance in ASC 260 Earnings Per Share. Loss per share is computed using the weighted average number of shares outstanding during the period. Diluted loss per share is equivalent to basic loss per share because the potential exercise of the equity-based financial instruments was anti-dilutive. i) Foreign Currency Translation The Company s operations are located in the United States of America and Canada, and it has offices in Canada. The Company maintains its accounting records in U.S. Dollars, as follows: At the transaction date, each asset, liability, revenue and expense that was acquired or incurred in a foreign currency is translated into U.S. dollars by using the exchange rate in effect at that date. At the period end, monetary assets and liabilities are translated at the exchange rate in effect at that date. The resulting foreign exchange gains and losses are included in profit or loss. j) Financial Instruments ASC 820 Fair Value Measurements and Disclosures, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and Level 3 - Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. The Company s financial instruments consist primarily of cash, marketable securities, accounts receivable, accounts payable and accrued liabilities, and due to related parties. The carrying amounts of cash, accounts and other receivable, accounts payable and accrued liabilities, and due to related parties approximate their fair values due to their short maturities or quoted market prices. The Company is located in Canada, which results in exposure to market risks from changes in foreign currency rates. The foreign currency exchange risk is the financial risk to the Company’s operations that arise from fluctuations in foreign exchange rates and the degree of volatility of these rates. Currently, the Company does not use derivative instruments to reduce its exposure to foreign currency risk as the Company does not hold a significant position in foreign currencies, such as the Canadian dollar, and the impact of a change in a few basis points for USD/CAD is not expected to be material. k) Income Taxes The Company applies the guidance in ASC 740, Income Taxes, which requires the Company to recognize deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns using the liability method. Under this method, deferred tax liabilities and assets are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the year in which the differences are expected to reverse. l) Impairment of Long-Lived Assets Long-lived assets, including equipment, and intangible assets, such as the Company s patents, are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss is recognized when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to the profit or loss. Intangible assets with indefinite lives are tested for impairment annually and in interim periods if certain events occur indicating that the carrying value of the intangible assets may be impaired. m) Comprehensive Income The Company applies ASC 220, Comprehensive Income, which establishes standards for reporting and presentation of comprehensive income, its components and accumulated balances. The Company discloses this information on its Statement of Stockholders Equity. Comprehensive income comprises equity changes except those transactions resulting from investments by owners and distributions to owners. n) Credit Risk and Receivable Concentration The Company places its cash with a high credit quality financial institution. As of August 31, 2019, the Company had approximately $1,285,147 in the bank (August 31, 2018: $1,727,184). As at August 31, 2019 we had $106,000 (2018 $199,375) in Intellectual Property Territory License fees receivable (Note 7) consisting of amounts due from three licensees (2018 three). These receivable amounts are based on contractual terms for payments that are payable within twelve months of signing the definitive agreements or routine IP Usage Fees. To date these licensees have performed all of their required obligations. The Company incurred $75,000 in bad debt in fiscal 2019. As at August 31, 2019, the Company had $161,418 (2018 - $61,176) in sales tax receivable (Note 6). The Company considers its credit risk to be low for such receivables. o) Commitments and Contingencies In accordance with ASC 450-20, Accounting for Contingencies, the Company records accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In the event that estimates or assumptions prove to differ from actual results, adjustments are made in subsequent periods to reflect more current information. Historically, the Company has not experienced any material claims. p) Research and Development Research and development costs are expensed as incurred.

Basis of Consolidation

Basis of Consolidation	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Consolidation	4. Basis of Consolidation These interim consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries; Lexaria CanPharm ULC, PoViva Corp., Lexaria Hemp Corp., Kelowna Management Services Corp. and Lexaria Pharmaceutical Corp., and our 83.333% subsidiary Lexaria Nicotine LLC (16.667% Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc.). All significant intercompany balances and transactions have been eliminated.	4. Basis of Consolidation These consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries; Lexaria CanPharm ULC, PoViva Corp., Lexaria Hemp Corp., Kelowna Management Services Corp. and Lexaria Pharmaceutical Corp, and our subsidiary Lexaria Nicotine LLC. On January 15, 2019, the Company announced the initial investment of $1,000,000 from Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc., for a 16.667% equity interest along with certain other rights in Lexaria Nicotine LLC. All significant intercompany balances and transactions have been eliminated.

Estimates and Judgments

Estimates and Judgments	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Estimates And Judgments [Abstract]
Estimates and Judgments	5. Estimates and Judgments The preparation of financial statements in conformity with U.S GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Some of the Company’s accounting policies require us to make subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are highly uncertain at the time the accounting estimates are made. Although we have used our best estimates based on facts and circumstances available to us at the time, different estimates reasonably could have been used. Changes in the accounting estimates used by the Company are reasonably likely to occur from time to time, which may have a material effect on the presentation of financial condition and results of operations. The Company reviews these estimates, judgments and assumptions periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable; however, actual results could differ from these estimates. In preparing these unaudited interim consolidated financial statements, the significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those applied to the audited consolidated financial statements for the year ended August 31, 2019.	5. Estimates and Judgments The preparation of financial statements in conformity with U.S GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Some of the Company’s accounting policies require us to make subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are highly uncertain at the time the accounting estimates are made. Although we have used our best estimates based on facts and circumstances available to us at the time, different estimates reasonably could have been used. Changes in the accounting estimates used by the Company are reasonably likely to occur from time to time, which may have a material effect on the presentation of financial condition and results of operations. The Company reviews these estimates, judgments and assumptions periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable; however, actual results could differ from these estimates. Significant accounting estimates and assumptions are used for, but not limited to: a) The Valuation of Deferred Tax Assets Judgement is required in determining whether deferred tax assets are recognized on the balance sheet. The recognition of deferred tax assets requires management to assess the likelihood that the Company will generate taxable income in future periods to utilize the deferred tax assets. Due to the Company s history of losses, deferred tax assets have not been recognized by Lexaria. b) Value of Stock Options and Warrants The Company provides compensation benefits to its employees, directors, officers, and consultants, through a stock option plan. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model. Expected volatility assumptions used in the model is based on the historical volatility of the Company s share price. The Company uses historical data to estimate the period of option exercises for use in the valuation model. The risk-free interest rate for the expected term of the option is based on the yields of government bonds. Changes in these assumptions, especially the share price volatility and the expected life determination could have a material impact on the Company s profit and loss for the periods presented. All estimates used in the model are based on historical data which may not be representative of future results.

Recent Accounting Guidance

Recent Accounting Guidance	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Guidance	6. Recent Accounting Guidance In February 2016 FASB issued ASU No. 201602, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation, and disclosure of leases for both lessees and the lessors. The new standard requires the lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. In November 2019 FASB issued ASU No 201910 revised the effective date based on updated criteria with the effective date for fiscal years beginning after December 15, 2020. The Company is assessing the impact on its consolidated financial statements. In June 2016, the FASB issued a new standard to replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. For trade and other receivables, loans and other financial instruments, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available for sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. In November 2019 FASB issued ASU No 201910 revised the effective date based on updated criteria with the effective date for fiscal years beginning after December 15, 2022. Application of the amendments is through a cumulative effect adjustment to deficit as of the effective date. The Company is currently assessing the impact of the standard on its consolidated financial statements. In February 2018, the FASB issued ASU No. 201802, Income Statement–Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act enacted by the U.S. federal government on December 22, 2017 (the “2017 Tax Act”). Consequently, the amendments eliminate the stranded tax effects resulting from the 2017 Tax Act and will improve the usefulness of information reported to financial statement users. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The Company adopted the ASU on September 1, 2019 for a $NIL effect. In June 2018, the FASB issued ASU No. 201807, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting. This is a simplification that involves several aspects of accounting for nonemployee share-based payments resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted the ASU on September 1, 2019 for a $NIL effect.	6. Recent Accounting Guidance In January 2016, FASB issued an ASU, Subtopic 82510, to amend certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. Most prominent among the amendments is the requirement for changes in fair value of equity investments, with certain exceptions, to be recognized through profit or loss rather than other comprehensive income. The Company adopted the standard September 1, 2018. The impact was not material and the $14,247 impact on the Company’s financial statements was included in income in the current period. In February 2016 FASB issued ASU No. 201602, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation, and disclosure of leases for both lessees and the lessors. The new standard requires the lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right of use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. When adopted, the Company does not expect this guidance to have a material impact on its consolidated financial statements. In June 2016, the FASB issued a new standard to replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. For trade and other receivables, loans and other financial instruments, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available for sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The new standard will be effective for Lexaria beginning September 1, 2020, with early adoption permitted. Application of the amendments is through a cumulative effect adjustment to deficit as of the effective date. The Company is currently assessing the impact of the standard on its consolidated financial statements. In February 2018, the FASB issued ASU No. 201802, Income Statement–Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act enacted by the U.S. federal government on December 22, 2017 (the “2017 Tax Act”). Consequently, the amendments eliminate the stranded tax effects resulting from the 2017 Tax Act and will improve the usefulness of information reported to financial statement users. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements and related disclosures but does not expect it to have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU No. 201807, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting. This is a simplification that involves several aspects of accounting for nonemployee share-based payments resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The new standard will be effective for Lexaria for September 1, 2019. The Company does not expect it to have a material impact on its consolidated financial statements.

Accounts and Other Receivables

Accounts and Other Receivables	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Accounts and Other Receivables	7. Accounts and Other Receivables February 29 August 31 2020 2019 $ $ Trade and deposits receivable 6,558 5,727 Territory license fee receivable 142,000 106,000 Sales tax receivable 78,708 161,418 227,266 273,145	7. Accounts and Other Receivables August 31 August 31 2019 2018 $ $ Trade and deposits receivable 5,727 5,200 Territory License Fee receivable 106,000 199,375 Sales tax receivable 161,418 61,176 273,145 265,751

Inventory

Inventory	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Inventory Disclosure [Abstract]
Inventory	8. Inventory February 29 2020 $ August 31 2019 $ Raw materials 55,743 45,068 Finished goods 68,669 82,328 124,412 127,396 During the period ended February 29, 2020, the Company wrote down $NIL (2019 - $NIL) of inventory to reflect its net realisable value.	8. Inventory August 31 August 31 2019 2018 $ $ Raw materials 45,068 29,355 Work in progress — 9,752 Finished goods 82,328 48,126 127,396 87,233 During the year ended August 31, 2019, the Company wrote down $7,182 (2018 - $12,966) of inventory to reflect its net realisable value.

Intellectual Property

Intellectual Property	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intellectual Property	9. Intellectual Property The following is a list of US capitalized patents held by the Company Issued Patent # Patent Issuance Date Patent Family US 9,474,725 B1 10/25/2016 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof US 9,839,612 B2 12/12/2017 US 9,972,680 B2 05/15/2018 US 9,974,739 B2 05/22/2018 US 10,084,044 B2 09/25/2018 US 10,103,225 B2 10/16/2018 US 10,381,440 08/13/2019 US 10,374,036 08/06/2019 The Company also holds non-capitalized patents outside the US. A continuity schedule for capitalized patents is presented below: February 29 August 31 2020 2019 $ $ Balance – beginning 265,127 146,538 Addition 5,711 122,982 Amortization* (2,843 ) (4,393 ) Balance – ending 267,995 265,127 *The patents are amortized over their legal life of 20 years.	9. Intellectual Property On November 12, 2014, the Company signed an agreement with Poppy’s Teas LLC. whereby it acquired a 51% interest. Subsequent to signing the agreement, Poppy’s Teas LLC effected a name change to PoViva Tea LLC. The Company acquired the remaining 49% ownership interest in PoViva Tea, LLC in October 2017 via compensation of $70,000, a waiver on certain debts owed to Lexaria, and a 5%, 20-year royalty on net profits of ViPova Tea TM The following is a list of US capitalized patents held by the Company Issued Patent # Patent Issuance Date Patent Family US 9,474,725 B1 10/25/2016 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof US 9,839,612 B2 12/12/2017 US 9,972,680 B2 05/15/2018 US 9,974,739 B2 05/22/2018 US 10,084,044 B2 09/25/2018 US 10,103,225 B2 10/16/2018 US 10,381,440 08/13/2019 US 10,374,036 08/06/2019 The Company also holds non-capitalized patents outside the US. A continuity schedule for patents is presented below: August 31 August 31 2019 2018 $ $ Balance – Beginning 146,538 62,827 Addition 122,982 85,399 Amortization* (4,393 ) (1,688 ) Balance – Ending 265,127 146,538 * The patents are amortized over their legal life of 20 years.

Property & Equipment

Property & Equipment	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Proceeds from Sale of Property, Plant, and Equipment [Abstract]
Property & Equipment	10. Property & Equipment Quarter Ended February 29, 2020 Cost Period Amortization Accumulated Amortization Net Balance February 29 2020 $ $ $ $ Leasehold improvements 259,981 (26,249 ) (59,592 ) 200,389 Computers 63,964 (9,841 ) (22,028 ) 41,936 Furniture fixtures equipment 34,220 (3,518 ) (9,580 ) 24,640 Lab equipment 291,235 (13,467 ) (20,013 ) 271,223 649,400 (53,075 ) (111,213 ) 538,188 Net Balance Year Ended August 31, 2019 Cost Period Amortization Accumulated Amortization August 31, 2019 $ $ $ $ Leasehold improvements 259,981 (33,342 ) (33,342 ) 226,639 Computers 63,964 (12,187 ) (12,187 ) 51,777 Furniture fixtures equipment 34,220 (4,205 ) (6,062 ) 28,158 Lab equipment 291,235 (6,546 ) (6,546 ) 284,689 649,400 (56,281 ) (58,137 ) 591,263	10. Property & Equipment Cost Period Amortization Accumulated Amortization Net Balance August 31, 2018 $ $ $ $ Equipment 3,094 (619 ) (1,857 ) 1,237 3,094 (619 ) (1,857 ) 1,237 Cost Period Amortization Accumulated Amortization Net Balance August 31, 2019 $ $ $ $ Leasehold improvements 259,981 (33,342 ) (33,342 ) 226,639 Computers 63,964 (12,187 ) (12,187 ) 51,777 Furniture fixtures equipment 34,220 (4,205 ) (6,062 ) 28,158 Lab equipment 291,235 (6,546 ) (6,546 ) 284,689 649,400 (56,281 ) (58,137 ) 591,263

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	11. Accounts Payable and Accrued Liabilities February 29 2020 $ August 31 2019 $ Accounts Payable Trades payable 55,593 31,463 Sales tax payable — 63,616 Accrued Liabilities Trades payable 6,097 41,332 Balance – ending 61,690 136,411	11. Accounts Payable and Accrued Liabilities August 31 August 31 2019 2018 $ $ Accounts Payable Trades Payable 31,463 14,378 Sales Tax Payable 63,616 1,869 Accrued Liabilities Trades Payable 41,332 19,538 Balance – Ending 136,411 35,785

Unearned Revenue

Unearned Revenue	12 Months Ended
	Aug. 31, 2019
Unearned Revenue [Abstract]
Unearned Revenue	12. Unearned Revenue On May 14, 2016, the Company entered into a licensing agreement (the “Licensing Agreement”) with an arm’s length party (the “Licensee”) allowing the Licensee, for a two-year period, to utilize the Company’s Technology to create, test, manufacture, and sell marijuana-infused consumable and/or topical products, in the state of Colorado, with an option of extending the terms of the Licensing Agreement to Washington, Oregon, and California (the “Territorial License”). In addition to the granting of the license, the Company is required to provide support services to the Licensee in connection with the use of the Company’s Technology during the term of the Licensing Agreement. The Company determined that the provision of the support services were a separate deliverable under the licensing agreement. Accordingly, the Company recognized revenue on a pro-rated basis over the term of the Licensing agreement. The Company has since determined that the support services form an insignificant portion of the licensing contract as they are primarily completed prior to delivery of the technology and that delivery of the license is complete when the Technology is transferred to the Licensee. During the year ended August 31, 2019, the Company recognized $Nil (2018 $17,083) (Note 14), of unearned revenue. August 31 2019 $ August 31 2018 $ Balance – Beginning — 17,083 Earned revenue (Note 15) — (17,083 ) Balance – Ending — —

Common Shares and Warrants

Common Shares and Warrants	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Equity [Abstract]
Common Shares and Warrants	12. Common Shares and Warrants During the quarter ended February 29, 2020 the Company issued 110,000 shares on the exercise of previously granted stock options for a total value of $11,000. A year to date summary of share issuances is presented below: Type of Issuance Number of Total Shares Value $ Option exercise 110,000 11,000 Private placement (1) 1,823,745 820,685 1,933,745 $ 831,685 (1) A continuity schedule for warrants is presented below: Number of Warrants Weighted Average Exercise Price $ Balance, August 31, 2018 3,286,274 0.72 Cancelled/Expired (17,498 ) 0.59 Exercised (1,626,513 ) 0.49 Issued 1,183,062 1.99 Balance, August 31, 2019 2,825,325 1.38 Cancelled/expired (750,000 ) 1.50 Issued 2,057,495 0.80 Balance February 29, 2020 4,132,820 1.07 The fair value of share purchase warrants granted was estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: February 29 2020 Expected volatility 91% Risk-free interest rate 2.87% Expected life 2 years Dividend yield 0.00% Estimated fair value per warrant $0.28 - $0.43 A summary of warrants outstanding as of February 29, 2020 is presented below: # of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 975,325 0.67 years 2.25 100,000 1.23 years 0.96 250,000 1.24 years 1.55 750,000 1.60 years 0.14 225,000 2.68 years 0.80 1,562,995 1.71 years 0.80 269,500 1.75 years 0.80 4,132,820 1.46 years 1.07	13. Common Shares and Warrants Fiscal 2019 Activity During the year ended August 31, 2019 the Company closed a non-brokered private placement for 947,150 Units priced at $1.60 each. Each Unit consists of one common share and one Share purchase warrant. Each warrant shall entitle the holder to acquire one common share at a price of $2.25 per Share for a period of 24 months. The Company also issued 28,175 broker warrants. The broker warrants have a term of 24 months and are each exercisable into one common share of the Company at a price of $2.25. The fair value of these broker warrants was determined to be $16,095, which were recorded as a share issue cost within additional paid in capital for a net effect of $Nil. The company granted a total of 107,737 broker warrants with a value of $6,484 that were recorded as a share issue cost within additional paid in capital for a net effect of $Nil. The company granted a total of 100,000 warrants pursuant to an agreement with a vendor valued at $52,817 that were recorded as an expense within investor relations. During the year ended August 31, 2018 the Company recognized $51,448 in consulting expense for warrants previously granted to a consultant upon vesting. Fiscal 2018 Activity On October 27, 2017 the Company extended the expiration date of warrants originally issued on January 9, 2017, with a one-year expiration date. The warrant quantity and exercise price remain unchanged, 500,000 warrants exercisable at $0.44, will now expire on January 9, 2019. There was a $Nil effect on the modification of the warrants. During the year ended August 31, 2018 the Company granted a total of 1,000,000 warrants with a fair value of $1,011,822 pursuant to consulting agreements signed during the year. The value of the warrants was recorded in consulting fees on the statement of operations. The company also granted a total of 35,913 warrants with a value of $21,646 which were recorded as a share issue cost within additional paid in capital for a net effect of $Nil. During the year ended August 31, 2018 the Company recognized $51,448 in consulting expense for warrants previously granted to a consultant upon vesting. A summary of share issuance is presented relating to option and warrant exercises, agreement requirements and debt settlement is presented below: Type of Issuance Number of Shares Total Value Warrant exercise (1) 1,626,513 796,122 Option exercise 430,000 66,250 Private placement 947,150 1,515,440 Per agreements (2) 250,000 234,500 3,253,663 $ 2,612,312 (1) Includes 384,212 broker warrants exercised for gross proceeds of $191,742 (2) The Company awarded the restricted common shares as required by consulting contracts A continuity schedule for warrants is presented below: Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2017 8,844,506 0.29 Cancelled/Expired (230,000 ) 0.17 Exercised (6,364,145 ) 0.28 Issued 1,035,913 1.48 Balance August 31, 2018 3,286,274 0.72 Cancelled/Expired (17,498 ) 0.59 Exercised (1,626,513 ) 0.49 Issued 1,183,062 1.99 Balance August 31, 2019 2,825,325 1.38 The fair value of share purchase warrants granted as broker warrants, compensation units, and compensatory warrants, was estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: August 31 2019 August 31 2018 Expected volatility 1% – 117% 100% – 154% Risk-free interest rate 2.31% – 2.87% 1.21% – 2.60% Expected life 1 day – 2 years 1.21 – 3 years Dividend yield 0.00% 0.00% Estimated fair value per warrant $Nil – $0.57 $0.40 – $1.48 A summary of warrants outstanding as of August 31, 2019 is presented below: # of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 250,000 0.25 years 0.83 500,000 0.38 years 1.83 975,325 1.17 years 2.25 100,000 1.73 years 0.96 250,000 1.73 years 1.55 750,000 2.11 years 0.14 2,825,325 1.27 years 1.38

Stock Options

Stock Options	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Options	13. Stock Options The Company has established its 2007 Equity Incentive Plan, whereby the board of directors may grant up to 412,500 stock options to eligible employees and directors, the 2010 Stock Option Plan whereby the board of directors may, from time to time, grant up to 1,512,500 stock options to officers 2014 Stock Option Plan whereby the board of directors may, from time to time, grant up to 1,997,500 stock options to directors, officers, employees, the board of directors may, from time to time, grant up to 7,838,713 stock options to directors, officers, employees, and consultants. Stock options granted must be exercised no later than five years The Company granted the following options during the quarter ended February 29, 2020: Quantity Exercise Price $ Life (Years) 550,000 0.47 5 60,000 (1) 0.43 5 610,000 0.47 (1) 20,000 on grant and 20,000 annually thereafter until fully vested. A continuity schedule for stock options is presented below: Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2018 4,800,000 0.71 Cancelled/expired (1,415,000 ) 0.66 Exercised (430,000 ) 0.15 Granted 2,048,000 1.00 Balance August 31, 2019 5,003,000 0.89 Cancelled/expired (550,000 ) 0.09 Exercised (110,000 ) 0.10 Granted 1,610,000 0.54 Balance February 29, 2020 (Outstanding) 5,953,000 0.88 3.69 94,510 Balance February 29, 2020 (Exercisable) 4,397,341 0.94 3.46 90,910 The fair value of options granted was estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: February 29 2020 Expected volatility 95%- Risk-free interest rate 1.45% Expected life 5 years Dividend yield 0.00% Estimated fair value per option $ 0.30 -	14. Stock Options The Company has established its 2007 Equity Incentive Plan, whereby the board of directors may grant up to 412,500 stock options to eligible employees and directors, the 2010 Stock Option Plan whereby the board of directors may, from time to time, grant up to 1,512,500 stock options to officers and employees, and its 2014 Stock Option Plan whereby the board of directors may, from time to time, grant up to 2,107,500 stock options to directors, officers, employees, and consultants, the Equity Incentive Plan whereby the board of directors may, from time to time, grant up to 7,838,713 stock options to directors, officers, employees, and consultants. Stock options granted must be exercised no later than five years from the date of grant or such lesser period as determined by the Company’s board of directors. The exercise price of an option is equal to or greater than the closing market price of the Company’s common shares on the day preceding the date of grant. The vesting terms of each grant are set by the board of directors. Fiscal 2019 Activity The Company granted in the period ending August 31, 2019: Quantity Exercise Price $ Life (Years) 390,000 (1) 1.27 5 240,000 (1) 1.06 5 30,000 (1) 1.16 5 350,000 0.99 5 440,000 (1) 0.99 5 48,000 (1) 0.96 5 100,000 0.81 5 450,000 (1) 0.81 5 2,048,000 1.00 (1) Fiscal 2018 Activity The Company granted in the period ending August 31, 2018, 200,000 stock options with an exercise price of $0.83 and an expiration date of December 1, 2022 to an officer of the Company, pursuant to an existing management contract and stock options with an exercise price of $1.53 to directors, officers, employees and consultants that enable the option holders to purchase up to 1,725,000 common shares of the Company. A continuity schedule for stock options is presented below: Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2017 3,320,875 0.15 Exercised (545,875 ) 0.17 Granted 2,025,000 1.49 Balance August 31, 2018 4,800,000 0.71 Expired/Cancelled (1,415,000 ) 0.66 Exercised (430,000 ) 0.15 Granted 2,048,000 1.00 Balance August 31, 2019 (Outstanding) 5,003,000 0.89 3.34 791,800 Balance August 31, 2019 (Exercisable) 3,961,000 0.90 3.03 752,300 The fair value of options granted was estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: August 31 2019 August 31 2018 Expected volatility 100% – 144% 127% – 131% Risk-free interest rate 1.42% – 2.89% 2.13% – 2.74% Expected life 5 years 5 years Dividend yield 0.00% 0.00% Estimated fair value per option $0.60 - $1.07 $0.70 – $1.73

Revenues

Revenues	6 Months Ended	12 Months Ended
	Feb. 28, 2019	Aug. 31, 2019
Revenues [Abstract]
Revenues	14. Revenues February 29 2020 $ February 28 2019 $ Product sales 99,191 5,436 Licensing revenue 69,750 32,000 Freight revenue 440 122 169,381 37,558 During the six months ended February 29, 2020, the Company recognized $37,750 of Intellectual Property Licensing fees and $36,000 of Usage Fees ( -$Nil and $32,000). Licensing revenues are significantly concentrated on a customer. There was an increase in product sales in the current year compared to the previous years as the Company was able to solve some payment processing issues late in fiscal 2019, allowing for improved ability to conduct online retail transactions. Intermediate products sales began during the second quarter, which typically is a DehydraTECH enabled powder that companies can purchase to include in their products. Intermediate product sales constituted the majority of our product sales segment revenue and is a new form of revenue for the current fiscal year. The Licensing fees consist of IP licensing fees for transfer of the Technology with the signing of definitive agreements for the DehydraTECH technology and usage fees. The Licensing fees include payments due upon transfer of the Technology and installment payments that are receivable within 12 months (Note 7).	15. Revenues August 31 2019 $ August 31 2018 $ Product sales 24,282 16,967 Licensing revenue (Note 11) 198,000 415,183 Freight revenue 328 1,137 222,610 433,287 The Company recognized licensing revenue on a pro-rated basis over the term of the Licensing Agreement and additional licensing fees as they were earned. The Company has determined that the support services form an insignificant portion of the licensing contract as they are substantially completed prior to delivery of the DehydraTECH™ technology (the Technology) and that delivery of the license is complete when the Technology is transferred to the licensee. Additional licensing fees and royalties are recognized as they are earned. During the year ended August 31, 2019, the Company recognized $Nil of deferred revenue (Note 12) and $198,000 of additional Intellectual Property Licensing fees. There was a slight increase in product sales in the current year compared to the previous years as the Company was able to solve some payment processing issues later in the fiscal year. The additional Licensing fees consist of IP licensing fees for transfer of the Technology with the signing of definitive agreements for the DehydraTECH technology. The additional Licensing fees include payments due upon transfer of the Technology and installment payments that are receivable within 12 months (Note 7).

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	15. Related Party Transactions February 29 February 28 2020 2019 Management, consulting Contract Non Cash Total Total and director services $ % $ % $ $ CAB Financial Services (1) 131,557 100 — — 131,557 92,319 M&E Services Ltd. (1) 58,785 100 — — 58,785 56,238 Docherty Management Limited (1) 113,569 38 187,069 62 300,638 83,263 Directors 35,214 100 — — 35,214 225,588 339,125 187,069 526,194 457,408 (1) Due to related parties: Related party transactions are recorded at the exchange amount established and agreed to between the related parties. As at $1,600 (August 31, 2019 - $48,096) was payable to related parties included in due to related parties.	16. Related Party Transactions Management, consulting and accounting services Cash $ % Non-Cash (2) $ % Aug 31 2019 Total $ Cash $ % Non-Cash (2) % Aug 31 2018 Total $ C.A.B Financial Services (1) 223,280 100 0 0 223,280 144,000 11 1,212,269 89 1,356,269 M&E Services Ltd. (1) 112,377 100 0 0 112,377 85,663 13 568,737 87 654,401 Docherty Management Limited (1) 195,740 100 0 0 195,740 140,471 11 1,148,152 89 1,288,622 Company controlled by a director 14,932 12 112,718 88 127,650 12,000 15 65,686 85 77,686 Directors 16,138 9 172,330 91 188,468 — 0 65,686 100 65,686 562,467 285,048 847,515 382,134 3,060,530 3,442,664 (1) (2) August 31, 2018 Common Shares Fair Value Cash Docherty Management (Note 13,16) (A) 345,250 $ 458,305 $ 164,361 CAB (Note 13,16) (B) 143,225 $ 192,195 $ 100,475 M&E Services Ltd (Note 13,16) 41,666 $ 34,166 — (A) (B) Due to related parties: As at August 31, 2019, $48,096 (August 31, 2018 - $7,855) was payable to related parties included in due to related parties. The related party transactions are recorded at the exchange amount established and agreed to between the related parties.

Segment Information

Segment Information	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Segment Reporting [Abstract]
Segment Information	16. Segment Information The operations involve the development and usage, including licensing, of its proprietary nutrient infusion Technology. Lexaria is centrally managed and its chief operating decision makers, being the President and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable segments: Intellectual Property Licensing and Consumer Products. Licensing revenues are significantly concentrated on one licensee. IP Licensing Consumer Products Corporate Consolidated Total $ $ $ $ External revenue 69,750 99,631 — 169,381 CoGS — (65,959 ) — (65,959 ) Operating expenses (300,034 ) (293,487 ) (1,432,156 ) (2,025,677 ) Segment loss (230,284 ) (259,815 ) (1,432,156 ) (1,922,255 ) Total assets 694,684 124,412 1,167,130 1,986,226	17. Segment Information The Company’s operations involve the development and usage, including licensing, of its proprietary nutrient infusion Technology. Lexaria is centrally managed and its chief operating decision makers, being the president and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The company has identified two reportable segments: Intellectual Property Licensing and Consumer Products. Licensing revenues are significantly concentrated on three licensees. IP Licensing Consumer Products Corporate Consolidated Total External Revenue $ 198,000 $ 24,610 $ — $ 222,610 CoGS $ — $ (22,893 ) $ — $ (22,893 ) Operating Expenses $ (1,211,733 ) $ (968,947 ) $ (2,177,450 ) $ (4,358,130 ) Segment Loss $ (1,013,733 ) $ (967,230 ) $ (2,177,450 ) $ (4,158,413 ) Total Assets $ 645,969 $ 127,396 $ 1,901,854 $ 2,675,219

Commitments, Significant Contra

Commitments, Significant Contracts and Contingencies	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments, Significant Contracts and Contingencies	17. Commitments, Significant Contracts and Contingencies Management and Service Agreements: As at February 29, 2020, the Company is party to the following contractual commitments: Party Monthly Commitment Expiry Date C.A.B Financial Services CAD $29,167 January 1, 2022 Docherty Management Ltd. CAD $25,000 January 1, 2022 M&E Services Ltd. CAD $12,960 June 1, 2021 Corporate development CAD $1,000 Month to Month Office management CAD $10,000 August 15, 2022 Research & development CAD $3,854 Month to Month Office rent (1) CAD $4,823 November 15, 2023 Corporate Offices (1)	18. Commitments, Significant Contracts and Contingencies Management and Service Agreements As at August 31, 2019, the Company is party to the following contractual commitments: Party Monthly Commitment Expiry Date C.A.B Financial Services (6) CAD $29,167 January 1, 2022 Docherty Management Ltd. (6) CAD $25,000 January 1, 2022 M&E Services Ltd. (1)(2) CAD $12,960 June 1, 2021 Corporate Development (3)(4) CAD $1,000 Month to Month Corporate Development (3)(4) CAD $8,000 Month to Month Investor relations and communications – Alex Blanchard Capital (1) CAD $7,500 Month to Month Office Management (7) CAD $10,000 August 15, 2022 Research & Development CAD $3,854 Month to Month Office Rent (5) CAD $4,823 November 15, 2023 Revenue Incentive Milestones (1) 100,000 common shares issuable upon the Company achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period for the first 12 months of the contract, plus a further 50,000 common shares issuable upon achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period, during the 13th - 24th months of the contract. If the Company achieves non-refundable revenues of $500,000 in any fiscal quarter, a further 200,000 common shares may be issuable during the first 12 months of the contract and 100,000 common shares during the 13th - 24th months of the contract. Intellectual Property Milestones (2) During the term of the agreement, for each provisional patent application substantively devised and successfully created, written, and filed with the U.S. Patent Office for the Company’s Technology, 250,000 restricted common shares of the Company will be issuable. Corporate Development Milestones (3) For new customers sourced by a Consultant for the first 12 months of the contract; for combined Lexaria Energy and ViPova products and including all combined sales efforts and/or technology licensing revenues, achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period would result in a restricted common share award of 100,000 Company shares (not achieved); and, during the 13th - 24th months of the contract; a restricted common share award of 50,000 Company shares may be achieved; this clause is limited to one payment per customer during the 12-month period, but payable on each customer that meets these sales/licensing thresholds. (4) For new customers sourced by a Consultant for the first 12 months of the contract; for combined Lexaria Energy and ViPova products and including all combined sales efforts and/or technology licensing revenues, achieving non-refundable revenues of $500,000 in any fiscal quarter would result in a restricted common share award of 200,000 Company shares (not achieved); and, during the 13th - 24th months of the contract; for combined Lexaria Energy and ViPova products and including all sales efforts, achieving non-refundable revenues of $500,000 in any fiscal quarter would result in a restricted common share award of 100,000 Company shares; this clause is limited to one payment per fiscal quarter. Corporate Offices (5) Corporate office and R&D lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years. Base rent is CDN$12.56 per square foot until November 14, 2019, CDN$12.86 per square foot until November 14, 2021 and CDN$13.21 per square foot until November 14, 2023 plus common area maintenance and taxes. Performance Incentives (6) A performance bonus equal to 50% of the annual compensation may be payable upon the completion of certain performance criteria as determined by the board of directors of Lexaria. Compensation equal to 2% of the consideration received by the Company from the sale of a subsidiary, excluding certain circumstances. Certain compensation to be paid upon a change of control excluding certain circumstances and participation in the Company’s approved stock option plans. (7) Compensation equal to 0.4% of the consideration received by the Company from the sale of a subsidiary, excluding certain circumstances. Certain compensation to be paid upon a change of control excluding certain circumstances and participation in the Company’s approved stock option plans.	[1],[2]
[1]	100,000 common shares issuable upon the Company achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period for the first 12 months of the contract, plus a further 50,000 common shares issuable upon achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period, during the 13th - 24th months of the contract. If the Company achieves non-refundable revenues of $500,000 in any fiscal quarter, a further 200,000 common shares may be issuable during the first 12 months of the contract and 100,000 common shares during the 13th - 24th months of the contract.
[2]	During the term of the agreement, for each provisional patent application substantively devised and successfully created, written, and filed with the U.S. Patent Office for the Company’s Technology, 250,000 restricted common shares of the Company will be issuable.

Prepaid Expenses

Prepaid Expenses	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Prepaid Expense, Current [Abstract]
Prepaid Expenses	18. Prepaid Expenses Prepaid expenses consist of the following at February 29, 2020 and August 31, 2019: February 29 2020 $ August 31 2019 $ Advertising & Conferences 37,955 39,143 Office & Insurance 9,042 29,784 Licence, Filing Fees, Dues 17,760 — 64,757 68,927	19. Prepaid Expenses Prepaid expenses consist of the following at August 31, 2019 and August 31, 2018: August 31 2019 $ August 31 2018 $ Advertising & Conferences 39,143 137,654 Consulting Fees — 4,555 Office & Insurance 29,784 21,533 Legal Fees — 29,990 68,927 193,732

Income Tax

Income Tax	12 Months Ended
	Aug. 31, 2019
Income Tax Disclosure [Abstract]
Income Tax	20. Income Tax The following table reconciles the income tax benefit at the U.S. Federal statutory rate to income tax benefit at the Company’s effective tax rates as at August 31, 2019 and 2018: August 31 2019 $ August 31 2018 $ Loss before taxes (4,158,413 ) (6,609,187 ) Expected income tax recovery (883,841 ) (1,322,068 ) Non-deductible items 8,544 2,724 Change in estimates 948 (54,057) Effect of changes in foreign and long-term tax rates — 1,816,659 Change in valuation allowance 874,349 (443,258 ) Total income taxes — — Deferred taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Deferred tax assets at August 31, 2019 and 2018 are comprised of the following: August 31 2019 $ August 31 2018 $ Non-capital losses 5,022,441 4,130,915 Marketable securities 2,300 1,789 Property plant and equipment — 24 Total unrecognized deferred tax assets 5,024,741 4,132,728 The Company has net operating loss carry-forwards of approximately $24,457,000 which may be carried forward to apply against future year income tax for U.S. tax purposes. Year Amount 2025 76,000 2026 508,000 2027 1,056,000 2028 720,000 2029 753,000 2030 552,000 2031 538,000 2032 252,000 2033 344,000 2034 3,257,000 2035 1,934,000 2036 1,150,000 2037 1,857,000 Indefinite 11,249,000 24,246,000

Marketable Securities

Marketable Securities	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Marketable Securities [Abstract]
Marketable Securities	19. Marketable Securities The components of Marketable Securities were as follows: Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2019 Common stock 81,250 9,335 (12,124 ) Total 81,250 9,335 (26,973 ) 63,612 February 29, 2020 Common stock 81,250 1,782 (41,771 ) Total 81,250 11,117 (68,744 ) 23,623 Unrealized losses from common stock are due to market price movements. Management does not believe any remaining unrealized losses represent other-than-temporary impairments based on our evaluation of available evidence.	21. Marketable Securities The components of Marketable Securities were as follows: Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2018 Common Stock 25,000 — (14,849 ) Total 25,000 — (14,849 ) 10,151 August 31, 2019 Common Stock 81,250 9,335 (12,124 ) Total 81,250 9,335 (26,973 ) 63,612 Unrealized losses from common stock are due to market price movements. Management does not believe any remaining unrealized losses represent other-than-temporary impairments based on our evaluation of available evidence.

Subsequent Events

Subsequent Events	12 Months Ended
	Aug. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	22. Subsequent Events November 5, 2019 the Company pursuant to certain consulting agreements issued a total of 1,000,000 stock options at $0.55 per Share for a period of five years; and 225,000 warrants at $0.80 for a period of three years. November 13, 2019 Lexaria closed the first tranche of its previously announced private placement. 1,554,245 units were issued at $0.45 for a total of $699,410.25. Each unit consists of one common share and one warrant exercisable at $0.80 until November 13, 2020, thereafter at $1.20 until November 13, 2021. The Company paid $3,937.50 and issued 8,750 broker warrants.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Accounting Policies [Abstract]
Accounting Principles	3. Significant Accounting Policies The significant accounting policies of the Company are consistent with those of our audited financial statements on Form 10-K for the year ended August 31, 2019.	a) Accounting Principles These consolidated financial statements have been prepared in conformity with generally accepted accounting principles of the United States of America. All amounts, unless otherwise stated, are in United States dollars.
Revenue Recognition		b) Revenue Recognition Product Revenue Revenue from the sale of products is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable, and collectability is reasonably assured, which typically occurs upon shipment. The Company reports its sales net of the amount of actual sales returns. Sales tax collected from customers is excluded from net sales. Licensing Revenue from Intellectual Property We recognize revenue for License fees at a point in time following the transfer of our intellectual property, our patented lipid nutrient infusion technology DehydraTECH™ for infusing Active Pharmaceutical Ingredients, to the licensee, which typically occurs on delivery of documentation. Usage Fees from Intellectual Property We recognize revenue for Usage fees when usage of our DehydraTECH intellectual property occurs by licensees infusing an Active Pharmaceutical Ingredient into one or more of their product lines for sale.
Inventory and Cost of Sales		c) Inventory and Cost of Sales The Company’s inventory consists of finished goods, work in progress, and raw materials. In all classes, inventory is valued at the lower of cost or market. Cost is determined on a first-in, first-out basis. Cost of sales includes all expenditures incurred in bringing the goods to the point of sale. Inventory costs and costs of sales include direct costs of the raw material, inbound freight charges, warehousing costs, handling costs (receiving and purchasing) and utilities and overhead expenses related to the Company’s manufacturing and processing facilities.
Cash and Cash Equivalents		d) Cash and Cash Equivalents Cash equivalents comprise certain highly liquid instruments with a maturity of three months or less when purchased. As of August 31, 2019, and August 31, 2018, the Company held cash only.
Equipment		e) Equipment Equipment is stated at cost less accumulated depreciation and impairment, and depreciated using the straight-line method over their useful lives or by units of production.
Patents		f) Patents Capitalized patent costs represent legal costs incurred to establish patents. When patents reach a mature stage, any associated legal costs are comprised mostly of maintenance fees and are expensed as incurred. Capitalized patent costs are amortized on a straight-line basis over the remaining life of the patent. The Company was granted its first patent on October 25, 2016, with a legal life of 20 years. Additional patent information is in Note 9.
Stock-Based Compensation		g) Stock-Based Compensation The Company accounts for its stock-based compensation awards in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized as expenses in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. Stock-based payments issued to non-employees are recorded at their fair values and are periodically revalued as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted to non-employees, the Company recognizes stock-based compensation expense on vesting.
Loss Per Share		h) Loss Per Share The Company applies the guidance in ASC 260 Earnings Per Share. Loss per share is computed using the weighted average number of shares outstanding during the period. Diluted loss per share is equivalent to basic loss per share because the potential exercise of the equity-based financial instruments was anti-dilutive.
Foreign Currency Translation		i) Foreign Currency Translation The Company s operations are located in the United States of America and Canada, and it has offices in Canada. The Company maintains its accounting records in U.S. Dollars, as follows: At the transaction date, each asset, liability, revenue and expense that was acquired or incurred in a foreign currency is translated into U.S. dollars by using the exchange rate in effect at that date. At the period end, monetary assets and liabilities are translated at the exchange rate in effect at that date. The resulting foreign exchange gains and losses are included in profit or loss.
Financial Instruments		j) Financial Instruments ASC 820 Fair Value Measurements and Disclosures, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities; Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and Level 3 - Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing. The Company s financial instruments consist primarily of cash, marketable securities, accounts receivable, accounts payable and accrued liabilities, and due to related parties. The carrying amounts of cash, accounts and other receivable, accounts payable and accrued liabilities, and due to related parties approximate their fair values due to their short maturities or quoted market prices. The Company is located in Canada, which results in exposure to market risks from changes in foreign currency rates. The foreign currency exchange risk is the financial risk to the Company’s operations that arise from fluctuations in foreign exchange rates and the degree of volatility of these rates. Currently, the Company does not use derivative instruments to reduce its exposure to foreign currency risk as the Company does not hold a significant position in foreign currencies, such as the Canadian dollar, and the impact of a change in a few basis points for USD/CAD is not expected to be material.
Income Taxes		k) Income Taxes The Company applies the guidance in ASC 740, Income Taxes, which requires the Company to recognize deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns using the liability method. Under this method, deferred tax liabilities and assets are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the year in which the differences are expected to reverse.
Impairment of Long-Lived Assets		l) Impairment of Long-Lived Assets Long-lived assets, including equipment, and intangible assets, such as the Company s patents, are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss is recognized when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to the profit or loss. Intangible assets with indefinite lives are tested for impairment annually and in interim periods if certain events occur indicating that the carrying value of the intangible assets may be impaired.
Comprehensive Income		m) Comprehensive Income The Company applies ASC 220, Comprehensive Income, which establishes standards for reporting and presentation of comprehensive income, its components and accumulated balances. The Company discloses this information on its Statement of Stockholders Equity. Comprehensive income comprises equity changes except those transactions resulting from investments by owners and distributions to owners.
Credit Risk and Receivable Concentration		n) Credit Risk and Receivable Concentration The Company places its cash with a high credit quality financial institution. As of August 31, 2019, the Company had approximately $1,285,147 in the bank (August 31, 2018: $1,727,184). As at August 31, 2019 we had $106,000 (2018 $199,375) in Intellectual Property Territory License fees receivable (Note 7) consisting of amounts due from three licensees (2018 three). These receivable amounts are based on contractual terms for payments that are payable within twelve months of signing the definitive agreements or routine IP Usage Fees. To date these licensees have performed all of their required obligations. The Company incurred $75,000 in bad debt in fiscal 2019. As at August 31, 2019, the Company had $161,418 (2018 - $61,176) in sales tax receivable (Note 6). The Company considers its credit risk to be low for such receivables.
Commitments and Contingencies		o) Commitments and Contingencies In accordance with ASC 450-20, Accounting for Contingencies, the Company records accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In the event that estimates or assumptions prove to differ from actual results, adjustments are made in subsequent periods to reflect more current information. Historically, the Company has not experienced any material claims.
Research and Development		p) Research and Development Research and development costs are expensed as incurred.
New Accounting Pronouncements, Policy [Policy Text Block]	6. Recent Accounting Guidance In February 2016 FASB issued ASU No. 201602, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation, and disclosure of leases for both lessees and the lessors. The new standard requires the lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. In November 2019 FASB issued ASU No 201910 revised the effective date based on updated criteria with the effective date for fiscal years beginning after December 15, 2020. The Company is assessing the impact on its consolidated financial statements. In June 2016, the FASB issued a new standard to replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. For trade and other receivables, loans and other financial instruments, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available for sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. In November 2019 FASB issued ASU No 201910 revised the effective date based on updated criteria with the effective date for fiscal years beginning after December 15, 2022. Application of the amendments is through a cumulative effect adjustment to deficit as of the effective date. The Company is currently assessing the impact of the standard on its consolidated financial statements. In February 2018, the FASB issued ASU No. 201802, Income Statement–Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act enacted by the U.S. federal government on December 22, 2017 (the “2017 Tax Act”). Consequently, the amendments eliminate the stranded tax effects resulting from the 2017 Tax Act and will improve the usefulness of information reported to financial statement users. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The Company adopted the ASU on September 1, 2019 for a $NIL effect. In June 2018, the FASB issued ASU No. 201807, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting. This is a simplification that involves several aspects of accounting for nonemployee share-based payments resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted the ASU on September 1, 2019 for a $NIL effect.

Accounts and Other Receivables

Accounts and Other Receivables (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Schedule of accounts and other receivables	February 29 August 31 2020 2019 $ $ Trade and deposits receivable 6,558 5,727 Territory license fee receivable 142,000 106,000 Sales tax receivable 78,708 161,418 227,266 273,145	August 31 August 31 2019 2018 $ $ Trade and deposits receivable 5,727 5,200 Territory License Fee receivable 106,000 199,375 Sales tax receivable 161,418 61,176 273,145 265,751

Inventory (Tables)

Inventory (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	February 29 2020 $ August 31 2019 $ Raw materials 55,743 45,068 Finished goods 68,669 82,328 124,412 127,396	August 31 August 31 2019 2018 $ $ Raw materials 45,068 29,355 Work in progress — 9,752 Finished goods 82,328 48,126 127,396 87,233

Intellectual Property (Tables)

Intellectual Property (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of patents	February 29 August 31 2020 2019 $ $ Balance – beginning 265,127 146,538 Addition 5,711 122,982 Amortization* (2,843 ) (4,393 ) Balance – ending 267,995 265,127 *The patents are amortized over their legal life of 20 years.	August 31 August 31 2019 2018 $ $ Balance – Beginning 146,538 62,827 Addition 122,982 85,399 Amortization* (4,393 ) (1,688 ) Balance – Ending 265,127 146,538 * The patents are amortized over their legal life of 20 years.

Property & Equipment (Tables)

Property & Equipment (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Proceeds from Sale of Property, Plant, and Equipment [Abstract]
Schedule of property & equipment	Quarter Ended February 29, 2020 Cost Period Amortization Accumulated Amortization Net Balance February 29 2020 $ $ $ $ Leasehold improvements 259,981 (26,249 ) (59,592 ) 200,389 Computers 63,964 (9,841 ) (22,028 ) 41,936 Furniture fixtures equipment 34,220 (3,518 ) (9,580 ) 24,640 Lab equipment 291,235 (13,467 ) (20,013 ) 271,223 649,400 (53,075 ) (111,213 ) 538,188 Net Balance Year Ended August 31, 2019 Cost Period Amortization Accumulated Amortization August 31, 2019 $ $ $ $ Leasehold improvements 259,981 (33,342 ) (33,342 ) 226,639 Computers 63,964 (12,187 ) (12,187 ) 51,777 Furniture fixtures equipment 34,220 (4,205 ) (6,062 ) 28,158 Lab equipment 291,235 (6,546 ) (6,546 ) 284,689 649,400 (56,281 ) (58,137 ) 591,263	Cost Period Amortization Accumulated Amortization Net Balance August 31, 2018 $ $ $ $ Equipment 3,094 (619 ) (1,857 ) 1,237 3,094 (619 ) (1,857 ) 1,237 Cost Period Amortization Accumulated Amortization Net Balance August 31, 2019 $ $ $ $ Leasehold improvements 259,981 (33,342 ) (33,342 ) 226,639 Computers 63,964 (12,187 ) (12,187 ) 51,777 Furniture fixtures equipment 34,220 (4,205 ) (6,062 ) 28,158 Lab equipment 291,235 (6,546 ) (6,546 ) 284,689 649,400 (56,281 ) (58,137 ) 591,263

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued liabilities	February 29 2020 $ August 31 2019 $ Accounts Payable Trades payable 55,593 31,463 Sales tax payable — 63,616 Accrued Liabilities Trades payable 6,097 41,332 Balance – ending 61,690 136,411	August 31 August 31 2019 2018 $ $ Accounts Payable Trades Payable 31,463 14,378 Sales Tax Payable 63,616 1,869 Accrued Liabilities Trades Payable 41,332 19,538 Balance – Ending 136,411 35,785

Unearned Revenue (Tables)

Unearned Revenue (Tables)	12 Months Ended
	Aug. 31, 2019
Unearned Revenue [Abstract]
Schedule of unearned revenue	August 31 2019 $ August 31 2018 $ Balance – Beginning — 17,083 Earned revenue (Note 15) — (17,083 ) Balance – Ending — —

Common Shares and Warrants (Tab

Common Shares and Warrants (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Equity [Abstract]
Schedule of option and warrant exercises	Type of Issuance Number of Total Shares Value $ Option exercise 110,000 11,000 Private placement (1) 1,823,745 820,685 1,933,745 $ 831,685	Type of Issuance Number of Shares Total Value Warrant exercise (1) 1,626,513 796,122 Option exercise 430,000 66,250 Private placement 947,150 1,515,440 Per agreements (2) 250,000 234,500 3,253,663 $ 2,612,312 (1) Includes 384,212 broker warrants exercised for gross proceeds of $191,742 (2) The Company awarded the restricted common shares as required by consulting contracts
Schedule of warrant	Number of Warrants Weighted Average Exercise Price $ Balance, August 31, 2018 3,286,274 0.72 Cancelled/Expired (17,498 ) 0.59 Exercised (1,626,513 ) 0.49 Issued 1,183,062 1.99 Balance, August 31, 2019 2,825,325 1.38 Cancelled/expired (750,000 ) 1.50 Issued 2,057,495 0.80 Balance February 29, 2020 4,132,820 1.07	Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2017 8,844,506 0.29 Cancelled/Expired (230,000 ) 0.17 Exercised (6,364,145 ) 0.28 Issued 1,035,913 1.48 Balance August 31, 2018 3,286,274 0.72 Cancelled/Expired (17,498 ) 0.59 Exercised (1,626,513 ) 0.49 Issued 1,183,062 1.99 Balance August 31, 2019 2,825,325 1.38
Schedule of warrants granted as compensation warrants by using the Black-Scholes option pricing model	February 29 2020 Expected volatility 91% Risk-free interest rate 2.87% Expected life 2 years Dividend yield 0.00% Estimated fair value per warrant $0.28 - $0.43	August 31 2019 August 31 2018 Expected volatility 1% – 117% 100% – 154% Risk-free interest rate 2.31% – 2.87% 1.21% – 2.60% Expected life 1 day – 2 years 1.21 – 3 years Dividend yield 0.00% 0.00% Estimated fair value per warrant $Nil – $0.57 $0.40 – $1.48
Schedule of warrants outstanding	# of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 975,325 0.67 years 2.25 100,000 1.23 years 0.96 250,000 1.24 years 1.55 750,000 1.60 years 0.14 225,000 2.68 years 0.80 1,562,995 1.71 years 0.80 269,500 1.75 years 0.80 4,132,820 1.46 years 1.07	# of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 250,000 0.25 years 0.83 500,000 0.38 years 1.83 975,325 1.17 years 2.25 100,000 1.73 years 0.96 250,000 1.73 years 1.55 750,000 2.11 years 0.14 2,825,325 1.27 years 1.38

Stock Options (Tables)

Stock Options (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of exercise price	Quantity Exercise Price $ Life (Years) 550,000 0.47 5 60,000 (1) 0.43 5 610,000 0.47 (1) 20,000 on grant and 20,000 annually thereafter until fully vested.	Quantity Exercise Price $ Life (Years) 390,000 (1) 1.27 5 240,000 (1) 1.06 5 30,000 (1) 1.16 5 350,000 0.99 5 440,000 (1) 0.99 5 48,000 (1) 0.96 5 100,000 0.81 5 450,000 (1) 0.81 5 2,048,000 1.00 (1)
Schedule of stock options	Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2018 4,800,000 0.71 Cancelled/expired (1,415,000 ) 0.66 Exercised (430,000 ) 0.15 Granted 2,048,000 1.00 Balance August 31, 2019 5,003,000 0.89 Cancelled/expired (550,000 ) 0.09 Exercised (110,000 ) 0.10 Granted 1,610,000 0.54 Balance February 29, 2020 (Outstanding) 5,953,000 0.88 3.69 94,510 Balance February 29, 2020 (Exercisable) 4,397,341 0.94 3.46 90,910	Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2017 3,320,875 0.15 Exercised (545,875 ) 0.17 Granted 2,025,000 1.49 Balance August 31, 2018 4,800,000 0.71 Expired/Cancelled (1,415,000 ) 0.66 Exercised (430,000 ) 0.15 Granted 2,048,000 1.00 Balance August 31, 2019 (Outstanding) 5,003,000 0.89 3.34 791,800 Balance August 31, 2019 (Exercisable) 3,961,000 0.90 3.03 752,300
Schedule of fair value of options granted	February 29 2020 Expected volatility 95%- Risk-free interest rate 1.45% Expected life 5 years Dividend yield 0.00% Estimated fair value per option $ 0.30 -	August 31 2019 August 31 2018 Expected volatility 100% – 144% 127% – 131% Risk-free interest rate 1.42% – 2.89% 2.13% – 2.74% Expected life 5 years 5 years Dividend yield 0.00% 0.00% Estimated fair value per option $0.60 - $1.07 $0.70 – $1.73

Revenues (Tables)

Revenues (Tables)	6 Months Ended
	Feb. 29, 2020
Revenues [Abstract]
Schedule of revenue	February 29 2020 $ February 28 2019 $ Product sales 99,191 5,436 Licensing revenue 69,750 32,000 Freight revenue 440 122 169,381 37,558

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Feb. 29, 2020
Related Party Transactions [Abstract]
Schedule of related party transactions	February 29 February 28 2020 2019 Management, consulting Contract Non Cash Total Total and director services $ % $ % $ $ CAB Financial Services (1) 131,557 100 — — 131,557 92,319 M&E Services Ltd. (1) 58,785 100 — — 58,785 56,238 Docherty Management Limited (1) 113,569 38 187,069 62 300,638 83,263 Directors 35,214 100 — — 35,214 225,588 339,125 187,069 526,194 457,408 (1)

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Feb. 29, 2020
Segment Reporting [Abstract]
Schedule of the profit or loss and total assets for each reportable segment	IP Licensing Consumer Products Corporate Consolidated Total $ $ $ $ External revenue 69,750 99,631 — 169,381 CoGS — (65,959 ) — (65,959 ) Operating expenses (300,034 ) (293,487 ) (1,432,156 ) (2,025,677 ) Segment loss (230,284 ) (259,815 ) (1,432,156 ) (1,922,255 ) Total assets 694,684 124,412 1,167,130 1,986,226

Commitments, Significant Cont_2

Commitments, Significant Contracts and Contingencies (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of management and service agreements	Party Monthly Commitment Expiry Date C.A.B Financial Services CAD $29,167 January 1, 2022 Docherty Management Ltd. CAD $25,000 January 1, 2022 M&E Services Ltd. CAD $12,960 June 1, 2021 Corporate development CAD $1,000 Month to Month Office management CAD $10,000 August 15, 2022 Research & development CAD $3,854 Month to Month Office rent (1) CAD $4,823 November 15, 2023 Corporate Offices (1)	Party Monthly Commitment Expiry Date C.A.B Financial Services (6) CAD $29,167 January 1, 2022 Docherty Management Ltd. (6) CAD $25,000 January 1, 2022 M&E Services Ltd. (1)(2) CAD $12,960 June 1, 2021 Corporate Development (3)(4) CAD $1,000 Month to Month Corporate Development (3)(4) CAD $8,000 Month to Month Investor relations and communications – Alex Blanchard Capital (1) CAD $7,500 Month to Month Office Management (7) CAD $10,000 August 15, 2022 Research & Development CAD $3,854 Month to Month Office Rent (5) CAD $4,823 November 15, 2023 Revenue Incentive Milestones (1) 100,000 common shares issuable upon the Company achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period for the first 12 months of the contract, plus a further 50,000 common shares issuable upon achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period, during the 13th - 24th months of the contract. If the Company achieves non-refundable revenues of $500,000 in any fiscal quarter, a further 200,000 common shares may be issuable during the first 12 months of the contract and 100,000 common shares during the 13th - 24th months of the contract. Intellectual Property Milestones (2) During the term of the agreement, for each provisional patent application substantively devised and successfully created, written, and filed with the U.S. Patent Office for the Company’s Technology, 250,000 restricted common shares of the Company will be issuable. Corporate Development Milestones (3) For new customers sourced by a Consultant for the first 12 months of the contract; for combined Lexaria Energy and ViPova products and including all combined sales efforts and/or technology licensing revenues, achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period would result in a restricted common share award of 100,000 Company shares (not achieved); and, during the 13th - 24th months of the contract; a restricted common share award of 50,000 Company shares may be achieved; this clause is limited to one payment per customer during the 12-month period, but payable on each customer that meets these sales/licensing thresholds. (4) For new customers sourced by a Consultant for the first 12 months of the contract; for combined Lexaria Energy and ViPova products and including all combined sales efforts and/or technology licensing revenues, achieving non-refundable revenues of $500,000 in any fiscal quarter would result in a restricted common share award of 200,000 Company shares (not achieved); and, during the 13th - 24th months of the contract; for combined Lexaria Energy and ViPova products and including all sales efforts, achieving non-refundable revenues of $500,000 in any fiscal quarter would result in a restricted common share award of 100,000 Company shares; this clause is limited to one payment per fiscal quarter. Corporate Offices (5) Corporate office and R&D lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years. Base rent is CDN$12.56 per square foot until November 14, 2019, CDN$12.86 per square foot until November 14, 2021 and CDN$13.21 per square foot until November 14, 2023 plus common area maintenance and taxes. Performance Incentives (6) A performance bonus equal to 50% of the annual compensation may be payable upon the completion of certain performance criteria as determined by the board of directors of Lexaria. Compensation equal to 2% of the consideration received by the Company from the sale of a subsidiary, excluding certain circumstances. Certain compensation to be paid upon a change of control excluding certain circumstances and participation in the Company’s approved stock option plans. (7) Compensation equal to 0.4% of the consideration received by the Company from the sale of a subsidiary, excluding certain circumstances. Certain compensation to be paid upon a change of control excluding certain circumstances and participation in the Company’s approved stock option plans.

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Prepaid Expense, Current [Abstract]
Schedule of prepaid expenses	February 29 2020 $ August 31 2019 $ Advertising & Conferences 37,955 39,143 Office & Insurance 9,042 29,784 Licence, Filing Fees, Dues 17,760 — 64,757 68,927	August 31 2019 $ August 31 2018 $ Advertising & Conferences 39,143 137,654 Consulting Fees — 4,555 Office & Insurance 29,784 21,533 Legal Fees — 29,990 68,927 193,732

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Marketable Securities [Abstract]
Schedule of marketable securities	Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2019 Common stock 81,250 9,335 (12,124 ) Total 81,250 9,335 (26,973 ) 63,612 February 29, 2020 Common stock 81,250 1,782 (41,771 ) Total 81,250 11,117 (68,744 ) 23,623	Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2018 Common Stock 25,000 — (14,849 ) Total 25,000 — (14,849 ) 10,151 August 31, 2019 Common Stock 81,250 9,335 (12,124 ) Total 81,250 9,335 (26,973 ) 63,612

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Aug. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of effective income tax rate reconciliation	August 31 2019 $ August 31 2018 $ Loss before taxes (4,158,413 ) (6,609,187 ) Expected income tax recovery (883,841 ) (1,322,068 ) Non-deductible items 8,544 2,724 Change in estimates 948 (54,057) Effect of changes in foreign and long-term tax rates — 1,816,659 Change in valuation allowance 874,349 (443,258 ) Total income taxes — —
Schedule of deferred taxes assets and liabilities	August 31 2019 $ August 31 2018 $ Non-capital losses 5,022,441 4,130,915 Marketable securities 2,300 1,789 Property plant and equipment — 24 Total unrecognized deferred tax assets 5,024,741 4,132,728
Schedule of carryforwards net operating loss	Year Amount 2025 76,000 2026 508,000 2027 1,056,000 2028 720,000 2029 753,000 2030 552,000 2031 538,000 2032 252,000 2033 344,000 2034 3,257,000 2035 1,934,000 2036 1,150,000 2037 1,857,000 Indefinite 11,249,000 24,246,000

Common Shares and Warrants (T_2

Common Shares and Warrants (Tables)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Equity [Abstract]
Schedule of option and warrant exercises	Type of Issuance Number of Total Shares Value $ Option exercise 110,000 11,000 Private placement (1) 1,823,745 820,685 1,933,745 $ 831,685	Type of Issuance Number of Shares Total Value Warrant exercise (1) 1,626,513 796,122 Option exercise 430,000 66,250 Private placement 947,150 1,515,440 Per agreements (2) 250,000 234,500 3,253,663 $ 2,612,312 (1) Includes 384,212 broker warrants exercised for gross proceeds of $191,742 (2) The Company awarded the restricted common shares as required by consulting contracts
Schedule of warrant	Number of Warrants Weighted Average Exercise Price $ Balance, August 31, 2018 3,286,274 0.72 Cancelled/Expired (17,498 ) 0.59 Exercised (1,626,513 ) 0.49 Issued 1,183,062 1.99 Balance, August 31, 2019 2,825,325 1.38 Cancelled/expired (750,000 ) 1.50 Issued 2,057,495 0.80 Balance February 29, 2020 4,132,820 1.07	Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2017 8,844,506 0.29 Cancelled/Expired (230,000 ) 0.17 Exercised (6,364,145 ) 0.28 Issued 1,035,913 1.48 Balance August 31, 2018 3,286,274 0.72 Cancelled/Expired (17,498 ) 0.59 Exercised (1,626,513 ) 0.49 Issued 1,183,062 1.99 Balance August 31, 2019 2,825,325 1.38
Schedule of warrants granted as compensation warrants by using the Black-Scholes option pricing model	February 29 2020 Expected volatility 91% Risk-free interest rate 2.87% Expected life 2 years Dividend yield 0.00% Estimated fair value per warrant $0.28 - $0.43	August 31 2019 August 31 2018 Expected volatility 1% – 117% 100% – 154% Risk-free interest rate 2.31% – 2.87% 1.21% – 2.60% Expected life 1 day – 2 years 1.21 – 3 years Dividend yield 0.00% 0.00% Estimated fair value per warrant $Nil – $0.57 $0.40 – $1.48
Schedule of warrants outstanding	# of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 975,325 0.67 years 2.25 100,000 1.23 years 0.96 250,000 1.24 years 1.55 750,000 1.60 years 0.14 225,000 2.68 years 0.80 1,562,995 1.71 years 0.80 269,500 1.75 years 0.80 4,132,820 1.46 years 1.07	# of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 250,000 0.25 years 0.83 500,000 0.38 years 1.83 975,325 1.17 years 2.25 100,000 1.73 years 0.96 250,000 1.73 years 1.55 750,000 2.11 years 0.14 2,825,325 1.27 years 1.38

Organization, Business and Go_2

Organization, Business and Going Concern (Detail Textuals)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Organization, Business And Going Concern [Abstract]
Date of incorporation	Dec. 9, 2004	Dec. 9, 2004
State of incorporation	NV	NV

Basis of Consolidation (Detail

Basis of Consolidation (Detail Textuals) - USD ($)	Feb. 29, 2020	Jan. 15, 2019
Lexaria Nicotine LLC
Equity interest percentage	83.333%
Altria Ventures Inc.
Equity interest percentage	16.667%	16.667%
Initial investment		$ 1,000,000

Significant Accounting Polici_2

Significant Accounting Policies (Detail Textuals)	12 Months Ended
	Aug. 31, 2019USD ($)License	Feb. 29, 2020USD ($)	Feb. 28, 2019USD ($)	Aug. 31, 2018USD ($)	Aug. 31, 2017USD ($)
Accounting Policies [Line Items]
Equipment, depreciation method	straight-line method
Patent, legal life	20 years
Cash	$ 1,285,147	$ 739,985	$ 3,093,211	$ 1,727,184	$ 2,533,337
Territory License Fee receivable	106,000	142,000		199,375
Bad debt expense	75,000
Sales tax receivable	$ 161,418	$ 78,708		$ 61,176
Intellectual Property Territory License
Accounting Policies [Line Items]
Number of licensees | License	3

Recent Accounting Guidance (Det

Recent Accounting Guidance (Detail Textuals)	12 Months Ended
	Aug. 31, 2019USD ($)
Accounting Changes and Error Corrections [Abstract]
Estimation impact on financial statements	$ 14,247

Accounts and Other Receivable_2

Accounts and Other Receivables (Details) - USD ($)	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Accounts and Financing Receivable, after Allowance for Credit Loss [Abstract]
Trade and deposits receivable	$ 6,558	$ 5,727	$ 5,200
Territory License Fee receivable	142,000	106,000	199,375
Sales tax receivable	78,708	161,418	61,176
Accounts and other receivable	$ 227,266	$ 273,145	$ 265,751

Inventory (Details)

Inventory (Details) - USD ($)	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 55,743	$ 45,068	$ 29,355
Work in progress		0	9,752
Finished goods	68,669	82,328	48,126
Inventory	$ 124,412	$ 127,396	$ 87,233

Inventory (Detail Textuals)

Inventory (Detail Textuals) - USD ($)	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Inventory Disclosure [Abstract]
Inventory writeoff (Note 8)	$ 7,182	$ 12,966

Intellectual Property (Details)

Intellectual Property (Details) - USD ($)	6 Months Ended		12 Months Ended
	Feb. 29, 2020		Aug. 31, 2019	Aug. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Balance - beginning	$ 265,127		$ 146,538	$ 62,827
Addition	5,711		122,982	85,399
Amortization	(2,843)	[1]	(4,393)	(1,688)
Balance - ending	$ 267,995		$ 265,127	$ 146,538
[1]	The patents are amortized over their legal life of 20 years.

Intellectual Property (Detail T

Intellectual Property (Detail Textuals) - USD ($)	2 Months Ended	6 Months Ended	12 Months Ended
	Oct. 31, 2017	Feb. 29, 2020	Aug. 31, 2019	Nov. 12, 2014
Alternative Health Products [Line Items]
Useful life		20 years	20 years
PoViva Tea, LLC
Alternative Health Products [Line Items]
Royalty percentage	5.00%
Equity interest percentage	49.00%
Amount of compensation	$ 70,000
Term of royalty contract	20 years
Poppy's Teas LLC
Alternative Health Products [Line Items]
Equity interest percentage				51.00%

Property & Equipment (Details)

Property & Equipment (Details) - USD ($)	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Equipment	$ 649,400	$ 649,400	$ 3,094
Less accumulated amortization	(111,213)	(58,137)	(1,857)
Balance - Ending	538,188	591,263	1,237
Period Amortization
Less accumulated amortization	(53,075)	(56,281)	(619)
Equipment
Equipment			3,094
Less accumulated amortization			(1,857)
Balance - Ending			1,237
Equipment | Period Amortization
Less accumulated amortization			$ (619)
Leasehold improvements
Equipment	259,981	259,981
Less accumulated amortization	(59,592)	(33,342)
Balance - Ending	200,389	226,639
Leasehold improvements | Period Amortization
Less accumulated amortization	(26,249)	(33,342)
Computers
Equipment	63,964	63,964
Less accumulated amortization	(22,028)	(12,187)
Balance - Ending	41,936	51,777
Computers | Period Amortization
Less accumulated amortization	(9,841)	(12,187)
Furniture fixtures equipment
Equipment	34,220	34,220
Less accumulated amortization	(9,580)	(6,062)
Balance - Ending	24,640	28,158
Furniture fixtures equipment | Period Amortization
Less accumulated amortization	(3,518)	(4,205)
Lab equipment
Equipment	291,235	291,235
Less accumulated amortization	(20,013)	(6,546)
Balance - Ending	271,223	284,689
Lab equipment | Period Amortization
Less accumulated amortization	$ (13,467)	$ (6,546)

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - USD ($)	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Accounts Payable And Accrued Liabilities[Line Items]
Accounts payable and accrued liabilities (Note 11)	$ 61,690	$ 136,411	$ 35,785
Accounts Payable
Accounts Payable And Accrued Liabilities[Line Items]
Trades payable	55,593	31,463	14,378
Sales Tax Payable	0	63,616	1,869
Accrued Liabilities
Accounts Payable And Accrued Liabilities[Line Items]
Trades payable	$ 6,097	$ 41,332	$ 19,538

Unearned Revenue (Details)

Unearned Revenue (Details) - USD ($)	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Unearned Revenue [Abstract]
Balance - Beginning	$ 0	$ 17,083
Earned revenue (Note 15)	0	(17,083)
Balance - Ending	$ 0	$ 0

Unearned Revenue (Detail Textua

Unearned Revenue (Detail Textuals) - USD ($)	May 14, 2016	Aug. 31, 2019	Aug. 31, 2018
Unearned Revenue [Abstract]
Term of licensing agreement	2 years
Earned revenue (Note 15)		$ 0	$ (17,083)

Common Shares and Warrants (Det

Common Shares and Warrants (Details) - USD ($)		3 Months Ended				6 Months Ended	12 Months Ended
		Feb. 29, 2020	May 31, 2019	Feb. 28, 2019	Nov. 30, 2018	Feb. 29, 2020	Aug. 31, 2019		Aug. 31, 2018
Equity [Abstract]
Number of Shares Warrant Exercise							1,626,513	[1]	6,364,145
Total Value Warrant Exercise	[1]						$ 796,122
Number of Shares Option Exercise						110,000	430,000		545,875
Total Value Option Exercise		$ 11,000	$ 14,750	$ 18,500	$ 33,000	$ 11,000	$ 66,250		$ 93,702
Private placement, number of Shares						1,823,745	947,150
Private placement, total Value						$ 820,685	$ 1,515,440
Number of Shares Per Agreement	[2]						250,000
Total Value Per Agreement	[2]						$ 234,500
Number of Shares							3,253,663
Total Value							$ 2,612,312
Total number of shares issued in exercise of options and private placement						1,933,745
Total value of shares issued in exercise of options and private placement						$ 831,685
[1]	Includes 384,212 broker warrants exercised for gross proceeds of $191,742
[2]	The Company awarded the restricted common shares as required by consulting contracts

Common Shares and Warrants (D_2

Common Shares and Warrants (Details 1) - $ / shares	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019		Aug. 31, 2018
Common Shares And Warrants [Roll Forward]
Number of Warrants, Balance	2,825,325	3,286,274		8,844,506
Weighted Average Exercise Price, Balance	$ 1.38	$ 0.72		$ 0.29
Number of Warrants, Cancelled/Expired	(750,000)	(17,498)		(230,000)
Weighted Average Exercise Price, Cancelled/Expired	$ 1.50	$ 0.59		$ 0.17
Number of Warrants, Exercised		(1,626,513)	[1]	(6,364,145)
Weighted Average Exercise Price, Exercised		$ 0.49		$ 0.28
Number of Warrants, Issued	2,057,495	1,183,062		1,035,913
Weighted Average Exercise Price, Issued	$ 0.80	$ 1.99		$ 1.48
Number of Warrants, Balance	4,132,820	2,825,325		3,286,274
Weighted Average Exercise Price, Balance	$ 1.07	$ 1.38		$ 0.72
[1]	Includes 384,212 broker warrants exercised for gross proceeds of $191,742

Common Shares and Warrants (D_3

Common Shares and Warrants (Details 2) - $ / shares	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	5 years
Dividend yield	0.00%
Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility	95.00%
Risk-free interest rate	1.45%
Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility	96.00%
Risk-free interest rate	1.68%
Warrant
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility	91.00%
Risk-free interest rate	2.87%
Expected life	2 years
Dividend yield	0.00%	0.00%	0.00%
Warrant | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility		1.00%	100.00%
Risk-free interest rate		2.31%	1.21%
Expected life		1 day	1 year 2 months 15 days
Estimated fair value per warrant	$ 0.28		$ 0.40
Warrant | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility		117.00%	154.00%
Risk-free interest rate		2.87%	2.60%
Expected life		2 years	3 years
Estimated fair value per warrant	$ 0.43	$ 0.57	$ 1.48

Common Shares and Warrants (D_4

Common Shares and Warrants (Details 3) - $ / shares	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2017
Number of Warrants	4,132,820	2,825,325	3,286,274	8,844,506
Weighted Average Remaining Contractual Life	1 year 5 months 15 days	1 year 3 months 7 days
Weighted Average Exercise Price	$ 1.07	$ 1.38	$ 0.44
Warrants 1
Number of Warrants	975,325	250,000
Weighted Average Remaining Contractual Life	8 months 1 day	3 months
Weighted Average Exercise Price	$ 2.25	$ 0.83
# of Warrants 100,000
Number of Warrants	100,000	500,000
Weighted Average Remaining Contractual Life	1 year 2 months 23 days	4 months 17 days
Weighted Average Exercise Price	$ 0.96	$ 1.83
# of Warrants 250,000
Number of Warrants	250,000	975,325
Weighted Average Remaining Contractual Life	1 year 2 months 26 days	1 year 2 months 1 day
Weighted Average Exercise Price	$ 1.55	$ 2.25
# of Warrants 750,000
Number of Warrants	750,000	100,000
Weighted Average Remaining Contractual Life	1 year 7 months 6 days	1 year 8 months 23 days
Weighted Average Exercise Price	$ 0.14	$ 0.96
# of Warrants 225,000
Number of Warrants	225,000	250,000
Weighted Average Remaining Contractual Life	2 years 8 months 4 days	1 year 8 months 23 days
Weighted Average Exercise Price	$ 0.80	$ 1.55
# of Warrants 1,562,995
Number of Warrants	1,562,995	750,000
Weighted Average Remaining Contractual Life	1 year 8 months 15 days	2 years 1 month 9 days
Weighted Average Exercise Price	$ 0.80	$ 0.14
# of Warrants 269,500
Number of Warrants	269,500
Weighted Average Remaining Contractual Life	1 year 9 months
Weighted Average Exercise Price	$ 0.80

Common Shares and Warrants (D_5

Common Shares and Warrants (Detail Textuals) - USD ($)	3 Months Ended				6 Months Ended	12 Months Ended
	Feb. 29, 2020	May 31, 2019	Feb. 28, 2019	Nov. 30, 2018	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Common Shares And Warrants [Line Items]
Value of stock options exercised	$ 11,000	$ 14,750	$ 18,500	$ 33,000	$ 11,000	$ 66,250	$ 93,702
Exercise of stock options (in shares)					110,000	430,000	545,875
Amount of private placement fees paid					$ 4,665
Payment for net receipt amount of private placement					$ 816,020
Each warrant entitles to purchase common share						1
Weighted Average Exercise Price	$ 1.07				$ 1.07	$ 1.38	$ 0.44
Number of units sold in private placement						947,150
Price per share of private placement units sold						$ 1.60
Exercise price of each whole compensation warrant exercisable						$ 2.25
Number of common share under each unit						1
Term of warrants						24 months
Number of warrants issued							500,000
Number of warrants issued as share issue cost							35,913
Fair value of warrants issued as share issue cost							$ 21,646
Consulting Expense For Warrants Previously Granted To Consultant Upon Vesting							$ 51,448
Collaborative Arrangement [Member]
Common Shares And Warrants [Line Items]
Number of warrants issued						100,000
Fair value of warrants issued						$ 52,817
Consulting agreements
Common Shares And Warrants [Line Items]
Number of warrants issued							1,000,000
Fair value of warrants issued							$ 1,011,822
Broker
Common Shares And Warrants [Line Items]
Exercise price of each whole compensation warrant exercisable						$ 2.25
Term of warrants						24 months
Number of brokers warrants exercisable						28,175
Number of warrants issued						107,737
Fair value of warrants issued						$ 16,095
Fair value of warrants issued as share issue cost						$ 6,484

Stock Options (Details)

Stock Options (Details) - $ / shares		3 Months Ended		6 Months Ended	12 Months Ended
		Feb. 29, 2020		Feb. 29, 2020	Aug. 31, 2019		Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Quantity		610,000			2,048,000
Exercise price		$ 0.47		$ 0.54	$ 1		$ 1.49
Stock Options 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Quantity		550,000			390,000	[1]
Exercise price		$ 0.47			$ 1.27
Life (Years)		5 years			5 years
Stock Options 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Quantity		60,000	[2]		240,000	[1]
Exercise price		$ 0.43			$ 1.06
Life (Years)		5 years			5 years
Stock Options 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Quantity	[1]				30,000
Exercise price					$ 1.16
Life (Years)					5 years
Stock Options 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Quantity	[1]				350,000
Exercise price					$ 0.99
Life (Years)					5 years
Stock Options 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Quantity	[1]				440,000
Exercise price					$ 0.99
Life (Years)					5 years
Stock Options 6
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Quantity	[1]				48,000
Exercise price					$ 0.96
Life (Years)					5 years
Stock Options 7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Quantity					100,000
Exercise price					$ 0.81
Life (Years)					5 years
Stock Options 8
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Quantity	[1]				450,000
Exercise price					$ 0.81
Life (Years)					5 years
[1]	Options granted vest over a period of three years
[2]	Options granted vest 20,000 on grant and 20,000 annually thereafter until fully vested.

Stock Options (Details 1)

Stock Options (Details 1) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Options
Balance outstanding		5,003,000	4,800,000	3,320,875
Expired		(550,000)	(1,415,000)
Exercised		(110,000)	(430,000)	(545,875)
Granted		1,610,000	2,048,000	2,025,000
Balance outstanding	5,953,000	5,953,000	5,003,000	4,800,000
Balance, Exercisable	4,397,341	4,397,341	3,961,000
Weighted Average Exercise Price
Balance outstanding		$ 0.89	$ 0.71	$ 0.15
Expired		0.09	0.66
Exercise Price		0.10	0.15	0.17
Granted	$ 0.47	0.54	1	1.49
Balance outstanding	0.88	0.88	0.89	$ 0.71
Balance, Exercisable	$ 0.94	$ 0.94	$ 0.90
Aggregate Intrinsic Value, Exercisable	$ 90,910	$ 90,910	$ 752,300
Aggregate Intrinsic Value, Outstanding	$ 94,510	$ 94,510	$ 791,800
Weighted Average Remaining Contractual Term, Exercisable		3 years 5 months 15 days	3 years 10 days
Weighted Average Remaining Contractual Term, Outstanding		3 years 8 months 8 days	3 years 4 months 2 days

Stock Options (Details 2)

Stock Options (Details 2) - $ / shares	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	5 years
Dividend yield	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Black-Scholes option	95.00%
Risk-free interest rate	1.45%
Estimated fair value per option	$ 0.30
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Black-Scholes option	96.00%
Risk-free interest rate	1.68%
Estimated fair value per option	$ 0.39
Black-Scholes option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life		5 years	5 years
Dividend yield		0.00%	0.00%
Black-Scholes option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Black-Scholes option		100.00%	127.00%
Risk-free interest rate		1.42%	2.13%
Estimated fair value per option		$ 0.60	$ 0.70
Black-Scholes option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Black-Scholes option		144.00%	131.00%
Risk-free interest rate		2.89%	2.74%
Estimated fair value per option		$ 1.07	$ 1.73

Stock Options (Detail Textuals)

Stock Options (Detail Textuals) - $ / shares	3 Months Ended		6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.47		$ 0.54	$ 1	$ 1.49
Term of expiration			5 years
Term of options vesting		3 years
Directors Officers Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant		1,725,000		1,725,000
Exercise price					$ 1.53
Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant					200,000
Exercise price					$ 0.83
Stock options expiration date					Dec. 1, 2022
2007 Equity incentive plan | Directors Officers Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant		7,838,713		7,838,713
2007 Equity incentive plan | Employees And Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant	412,500	412,500	412,500	412,500
2019 Equity Incentive Plan | Directors Officers Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant	7,838,713		7,838,713
2014 Stock Option Plan | Directors Officers Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant	1,997,500	2,107,500	1,997,500	2,107,500
2010 Stock Option Plan | Officers And Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options available for grant	1,512,500	1,512,500	1,512,500	1,512,500
Stock Options 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.47			$ 1.27
Stock Options 1 | On grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options vested	20,000
Stock Options 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.43			$ 1.06
Stock Options 2 | Annually thereafter until fully vested
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options vested	20,000

Revenues (Details)

Revenues (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019	Aug. 31, 2019	Aug. 31, 2018
Revenue [Line Items]
Revenue	$ 107,299	$ 15,349	$ 169,381	$ 37,558	$ 222,610	$ 433,287
Product sales
Revenue [Line Items]
Revenue			99,191	5,436	24,282	16,967
Licensing revenue
Revenue [Line Items]
Revenue			69,750	32,000	198,000	415,183
Freight revenue
Revenue [Line Items]
Revenue			$ 440	$ 122	$ 328	$ 1,137

Revenues (Detail Textuals)

Revenues (Detail Textuals) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019	Aug. 31, 2019	Aug. 31, 2018
Disaggregation of Revenue [Line Items]
Licensing revenue	$ 107,299	$ 15,349	$ 169,381	$ 37,558	$ 222,610	$ 433,287
Revenue from additional intellectual property licensing fees					$ 198,000
Intellectual Property Licensing fees
Disaggregation of Revenue [Line Items]
Licensing revenue			37,750
Usage Fees
Disaggregation of Revenue [Line Items]
Licensing revenue			$ 36,000	$ 32,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)		6 Months Ended				12 Months Ended
		Feb. 29, 2020		Feb. 28, 2019		Aug. 31, 2019		Aug. 31, 2018
Related Party Transaction [Line Items]
Cash		$ 339,125				$ 562,467		$ 382,134
Non-Cash		187,069				285,048	[1]	3,060,530	[1]
Management, consulting and accounting services		526,194		$ 457,408		847,515		3,442,664
C.A.B Financial Services Ltd. ("CAB")
Related Party Transaction [Line Items]
Cash		$ 131,557	[2]			$ 223,280	[3]	$ 144,000	[3]
Percentage of cash		100.00%	[2]			100.00%	[3]	11.00%	[3]
Non-Cash		$ 0	[2]			$ 0		$ 1,212,269	[1],[3]
Percentage of non cash		0.00%	[2]			0.00%		89.00%	[3]
Management, consulting and accounting services		$ 131,557	[2]	92,319	[2]	$ 223,280	[3]	$ 1,356,269	[3]
M&E Services Ltd. ("M&E")
Related Party Transaction [Line Items]
Cash		$ 58,785	[2]			$ 112,377	[3]	$ 85,663	[3]
Percentage of cash		100.00%	[2]			100.00%	[3]	13.00%	[3]
Non-Cash		$ 0	[2]			$ 0		$ 568,737	[1],[3]
Percentage of non cash		0.00%	[2]			0.00%		87.00%	[3]
Management, consulting and accounting services		$ 58,785	[2]	56,238	[2]	$ 112,377	[3]	$ 654,401	[3]
Docherty Management Limited ("Docherty Management")
Related Party Transaction [Line Items]
Cash		$ 113,569	[2]			$ 195,740	[3]	$ 140,471	[3]
Percentage of cash		38.00%	[2]			100.00%	[3]	11.00%	[3]
Non-Cash		$ 187,069	[2]			$ 0		$ 1,148,152	[1],[3]
Percentage of non cash		62.00%	[2]			0.00%		89.00%	[3]
Management, consulting and accounting services		$ 300,638	[2]	83,263	[2]	$ 195,740	[3]	$ 1,288,622	[3]
Company controlled by a director Consulting
Related Party Transaction [Line Items]
Cash						$ 14,932		$ 12,000
Percentage of cash						12.00%		15.00%
Non-Cash	[1]					$ 112,718		$ 65,686
Percentage of non cash						88.00%		85.00%
Management, consulting and accounting services						$ 127,650		$ 77,686
Directors
Related Party Transaction [Line Items]
Cash		$ 35,214				$ 16,138		$ 0
Percentage of cash		100.00%				9.00%		0.00%
Non-Cash		$ 0				$ 172,330	[1]	$ 65,686	[1]
Percentage of non cash		0.00%				91.00%		100.00%
Management, consulting and accounting services		$ 35,214		$ 225,588		$ 188,468		$ 65,686
[1]	Stock Based Compensation (SBC) and Share Awards are included in the total value of the grants and awards included in expenses. In the year ended August 31, 2019 the Company granted no option or awards to officers and $285,048 awards to Directors included in Consulting expense. In the year ended August 31, 2018 the Company granted a total of 1,700,000 incentive stock options to officers and directors of the Company with a fair value of $2,111,028 and included in Consulting expense (Note 14).
[2]	C.A.B. Financial Services is owned by the CEO of the Company, M&E Services Ltd. is owned by the CFO of the Company, and Docherty Management Limited is owned by the President of the Company.
[3]	C.A.B. Financial Services is owned by the CEO of the Company, ME Services Ltd. is owned by the CFO of the Company (as of June 1 2017), and Docherty Management Limited is owned by the President of the Company.

Related Party Transactions (D_2

Related Party Transactions (Details 1)	12 Months Ended
	Aug. 31, 2018USD ($)shares
Docherty Management Limited ("Docherty Management")
Related Party Transaction [Line Items]
Common Shares | shares	345,250	[1]
Fair Value	$ 458,305	[1]
Cash	$ 164,361	[1]
C.A.B Financial Services Ltd. ("CAB")
Related Party Transaction [Line Items]
Common Shares | shares	143,225	[2]
Fair Value	$ 192,195	[2]
Cash	$ 100,475	[2]
M&E Services Ltd. ("M&E")
Related Party Transaction [Line Items]
Common Shares | shares	41,666
Fair Value	$ 34,166
[1]	Issued in lieu of issuance of 466,666 common shares, as mutually agreed to between the parties.
[2]	Issued in lieu of issuance of 216,670 common shares, as mutually agreed to between the parties.

Related Party Transactions (D_3

Related Party Transactions (Detail Textuals) - USD ($)	6 Months Ended		12 Months Ended
	Feb. 29, 2020		Aug. 31, 2019		Aug. 31, 2018
Related Party Transaction [Line Items]
Due to related parties	$ 1,600		$ 48,096		$ 7,855
Granted	1,610,000		2,048,000		2,025,000
Non-Cash	$ 187,069		$ 285,048	[1]	$ 3,060,530	[1]
Docherty Management Limited ("Docherty Management")
Related Party Transaction [Line Items]
Non-Cash	187,069	[2]	0		1,148,152	[1],[3]
C.A.B Financial Services Ltd. ("CAB")
Related Party Transaction [Line Items]
Non-Cash	0	[2]	0		1,212,269	[1],[3]
M&E Services Ltd. ("M&E")
Related Party Transaction [Line Items]
Non-Cash	$ 0	[2]	$ 0		$ 568,737	[1],[3]
[1]	Stock Based Compensation (SBC) and Share Awards are included in the total value of the grants and awards included in expenses. In the year ended August 31, 2019 the Company granted no option or awards to officers and $285,048 awards to Directors included in Consulting expense. In the year ended August 31, 2018 the Company granted a total of 1,700,000 incentive stock options to officers and directors of the Company with a fair value of $2,111,028 and included in Consulting expense (Note 14).
[2]	C.A.B. Financial Services is owned by the CEO of the Company, M&E Services Ltd. is owned by the CFO of the Company, and Docherty Management Limited is owned by the President of the Company.
[3]	C.A.B. Financial Services is owned by the CEO of the Company, ME Services Ltd. is owned by the CFO of the Company (as of June 1 2017), and Docherty Management Limited is owned by the President of the Company.

Segment Information (Details)

Segment Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Feb. 29, 2020	Feb. 28, 2019	Aug. 31, 2019	Aug. 31, 2018
External revenue	$ 107,299	$ 15,349	$ 169,381	$ 37,558	$ 222,610	$ 433,287
CoGS	(58,106)	(2,690)	(65,959)	(4,848)	(22,893)	(25,185)
Operating expenses	(1,046,685)	(1,165,770)	(2,025,677)	(1,887,212)	(4,358,130)	(7,017,289)
Segment Loss	(997,492)	$ (1,153,111)	(1,922,255)	$ (1,854,502)	(4,158,413)	(6,609,187)
Total assets	1,986,226		1,986,226		2,675,219	$ 2,431,826
IP Licensing
External revenue			69,750		198,000
CoGS			0		0
Operating expenses			(300,034)		(1,211,733)
Segment Loss			(230,284)		(1,013,733)
Total assets	694,684		694,684		645,969
Consumer Products
External revenue			99,631		24,610
CoGS			(65,959)		(22,893)
Operating expenses			(293,487)		(968,947)
Segment Loss			(259,815)		(967,230)
Total assets	124,412		124,412		127,396
Corporate
External revenue			0		0
CoGS			0		0
Operating expenses			(1,432,156)		(2,177,450)
Segment Loss			(1,432,156)		(2,177,450)
Total assets	$ 1,167,130		$ 1,167,130		$ 1,901,854

Segment Information (Detail Tex

Segment Information (Detail Textuals)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Segment Reporting [Abstract]
Number of reportable segments	2	2

Commitments, Significant Cont_3

Commitments, Significant Contracts and Contingencies (Details) - CAD ($)		6 Months Ended		12 Months Ended
		Feb. 29, 2020		Aug. 31, 2019
C.A.B Financial Services
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment		$ 29,167		$ 29,167	[1]
Expiry Date		January 1, 2022		January 1, 2022
Docherty Management Ltd.
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment		$ 25,000		$ 25,000	[1]
Expiry Date		January 1, 2022		January 1, 2022
M&E Services Ltd.
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment		$ 12,960		$ 12,960	[1]
Expiry Date		June 1, 2021		June 1, 2021
Corporate development
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment		$ 1,000		$ 1,000	[2],[3]
Expiry Date		Month to Month		Month to Month
Corporate development
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	[2],[3]			$ 8,000
Expiry Date				Month to Month
Investor relations and communications - Alex Blanchard Capital
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment	[4]			$ 7,500
Expiry Date				Month to Month
Office management
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment		$ 10,000		$ 10,000	[5]
Expiry Date		August 15, 2022		August 15, 2022
Research & development
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment		$ 3,854		$ 3,854
Expiry Date		Month to Month		Month to Month
Office rent
Commitments Significant Contracts And Contingencies [Line Items]
Monthly Commitment		$ 4,823	[6]	$ 4,823	[7]
Expiry Date		November 15, 2023	[6]	November 15, 2023
[1]	A performance bonus equal to 50% of the annual compensation may be payable upon the completion of certain performance criteria as determined by the board of directors of Lexaria. Compensation equal to 2% of the consideration received by the Company from the sale of a subsidiary, excluding certain circumstances. Certain compensation to be paid upon a change of control excluding certain circumstances and participation in the Company’s approved stock option plans.
[2]	For new customers sourced by a Consultant for the first 12 months of the contract; for combined Lexaria Energy and ViPova products and including all combined sales efforts and/or technology licensing revenues, achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period would result in a restricted common share award of 100,000 Company shares (not achieved); and, during the 13th - 24th months of the contract; a restricted common share award of 50,000 Company shares may be achieved; this clause is limited to one payment per customer during the 12-month period, but payable on each customer that meets these sales/licensing thresholds.
[3]	For new customers sourced by a Consultant for the first 12 months of the contract; for combined Lexaria Energy and ViPova products and including all combined sales efforts and/or technology licensing revenues, achieving non-refundable revenues of $500,000 in any fiscal quarter would result in a restricted common share award of 200,000 Company shares (not achieved); and, during the 13th - 24th months of the contract; for combined Lexaria Energy and ViPova products and including all sales efforts, achieving non-refundable revenues of $500,000 in any fiscal quarter would result in a restricted common share award of 100,000 Company shares; this clause is limited to one payment per fiscal quarter.
[4]	100,000 common shares issuable upon the Company achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period for the first 12 months of the contract, plus a further 50,000 common shares issuable upon achieving non-refundable revenues of $200,000 to any single customer in any consecutive 60-day period, during the 13th - 24th months of the contract. If the Company achieves non-refundable revenues of $500,000 in any fiscal quarter, a further 200,000 common shares may be issuable during the first 12 months of the contract and 100,000 common shares during the 13th - 24th months of the contract.
[5]	For new customers sourced by a Consultant for the first 12 months of the contract; for combined Lexaria Energy and ViPova products and including all combined sales efforts and/or technology licensing revenues, achieving non-refundable revenues of $500,000 in any fiscal quarter would result in a restricted common share award of 200,000 Company shares (not achieved); and, during the 13th - 24th months of the contract; for combined Lexaria Energy and ViPova products and including all sales efforts, achieving non-refundable revenues of $500,000 in any fiscal quarter would result in a restricted common share award of 100,000 Company shares; this clause is limited to one payment per fiscal quarter.
[6]	Corporate office and RD lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years.
[7]	Corporate office and R lab space leased in Kelowna, British Columbia, Canada until November 15, 2023 with an option to extend an additional five years. Base rent is CDN$12.56 per square foot until November 14, 2019, CDN$12.86 per square foot until November 14, 2021 and CDN$13.21 per square foot until November 14, 2023 plus common area maintenance and taxes.

Commitments, Significant Cont_4

Commitments, Significant Contracts and Contingencies (Detail Textuals) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019
Commitments Significant Contracts And Contingencies [Line Items]
Percentages of performance bonus annual compensation		50.00%
Percentages of consideration received from sale of subsidiary		0.02
During first 12 months of the contract | Corporate Development Milestones 1
Commitments Significant Contracts And Contingencies [Line Items]
Shares issuable by meeting milestone		100,000
Non-refundable revenues threshold		$ 200,000
During first 12 months of the contract | Corporate Development Milestones 2
Commitments Significant Contracts And Contingencies [Line Items]
Shares issuable by meeting milestone		200,000
Non-refundable revenues threshold		$ 500,000
During the 13th to 24th months of the contract | Revenue Incentive Milestones
Commitments Significant Contracts And Contingencies [Line Items]
Non-refundable revenues threshold		$ 200,000
During the 13th to 24th months of the contract | Corporate Development Milestones 1
Commitments Significant Contracts And Contingencies [Line Items]
Shares issuable by meeting milestone		50,000
During the 13th to 24th months of the contract | Corporate Development Milestones 2
Commitments Significant Contracts And Contingencies [Line Items]
Non-refundable revenues threshold		$ 500,000
Any fiscal quarter during first 12 months of the contract | Revenue Incentive Milestones
Commitments Significant Contracts And Contingencies [Line Items]
Shares issuable by meeting milestone		200,000
Non-refundable revenues threshold	$ 500,000
Until November 14, 2019 | Corporate Offices
Commitments Significant Contracts And Contingencies [Line Items]
Shares issuable by meeting milestone		100,000
Non-refundable revenues threshold		$ 200,000
Base rent per square foot		12.56
Until November 14, 2023 | Corporate Offices
Commitments Significant Contracts And Contingencies [Line Items]
Base rent per square foot		$ 13.21
Any fiscal quarter during the 13th to 24th months of the contract | Revenue Incentive Milestones
Commitments Significant Contracts And Contingencies [Line Items]
Shares issuable by meeting milestone		100,000
Until November 14, 2021 | Corporate Offices
Commitments Significant Contracts And Contingencies [Line Items]
Base rent per square foot		$ 12.86

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Prepaid Expense, Current [Abstract]
Advertising & Conferences	$ 37,955	$ 39,143	$ 137,654
Consulting Fees		0	4,555
Office & Insurance	9,042	29,784	21,533
Licence, Filing Fees, Dues	17,760	0	29,990
Prepaid expenses	$ 64,757	$ 68,927	$ 193,732

Marketable Securities (Details)

Marketable Securities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 29, 2020	Aug. 31, 2019	Aug. 31, 2018
Marketable Securities [Line Items]
Cost Basis	$ 81,250	$ 81,250	$ 25,000
Unrealized Gains	11,117	9,335	0
Unrealized Losses	(68,744)	(26,973)	(14,849)
Total	23,623	64,214	10,151
Common stock
Marketable Securities [Line Items]
Cost Basis	81,250	81,250	25,000
Unrealized Gains	1,782	9,335	0
Unrealized Losses	$ (41,771)	$ (12,124)	$ (14,849)

Income Tax (Details)

Income Tax (Details) - USD ($)	12 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Income Tax Disclosure [Abstract]
Loss before taxes	$ (4,158,413)	$ (6,609,187)
Expected income tax recovery	(883,841)	(1,322,068)
Non-deductible items	8,544	2,724
Change in estimates	948	(54,057)
Effect of changes in foreign and long-term tax rates	0	1,816,659
Change in valuation allowance	874,349	(443,258)
Total income taxes	$ 0	$ 0

Income Tax (Details 1)

Income Tax (Details 1) - USD ($)	Aug. 31, 2019	Aug. 31, 2018
Income Tax Disclosure [Abstract]
Non-capital losses	$ 5,022,441	$ 4,130,915
Marketable securities	2,300	1,789
Property plant and equipment	0	24
Total unrecognized deferred tax assets	$ 5,024,741	$ 4,132,728

Income Tax (Details 2)

Income Tax (Details 2)	Aug. 31, 2019USD ($)
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 24,246,000
2025
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	76,000
2026
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	508,000
2027
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	1,056,000
2028
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	720,000
2029
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	753,000
2030
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	552,000
2031
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	538,000
2032
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	252,000
2033
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	344,000
2034
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	3,257,000
2035
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	1,934,000
2036
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	1,150,000
2037
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	1,857,000
Indefinite
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 11,249,000

Income Tax (Detail Textuals)

Income Tax (Detail Textuals)	Aug. 31, 2019USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 24,246,000

Subsequent Events (Detail Textu

Subsequent Events (Detail Textuals) - USD ($)	2 Months Ended		3 Months Ended		12 Months Ended
	Nov. 13, 2019	Nov. 05, 2019	Nov. 30, 2019	Nov. 30, 2018	Aug. 31, 2019	Aug. 31, 2018	Feb. 29, 2020
Subsequent Event [Line Items]
Number of units sold in private placement					947,150
Private placement of shares, net of issuance cost			$ 816,020	$ 1,470,310	$ 1,470,310
Price per share of private placement units sold					$ 1.60
Number of common share under each unit					1
Each warrant entitles to purchase common share					1
Term of warrants					24 months
Number of warrants issued						500,000
Exercise price of warrants					$ 1.38	$ 0.44	$ 1.07
Consulting agreements
Subsequent Event [Line Items]
Number of warrants issued						1,000,000
Subsequent Events
Subsequent Event [Line Items]
Number of units sold in private placement	1,554,245
Private placement of shares, net of issuance cost	$ 699,410.25
Price per share of private placement units sold	$ 0.45
Number of common share under each unit	1
Each warrant entitles to purchase common share	1
Number of warrant issued to broker	8,750
Subsequent Events | November 13, 2020
Subsequent Event [Line Items]
Exercise price of warrants	$ 0.80
Subsequent Events | November 13, 2021
Subsequent Event [Line Items]
Exercise price of warrants	$ 1.20
Subsequent Events | Consulting agreements
Subsequent Event [Line Items]
Shares issued for services (Shares)		1,000,000
Shares issued price per share		$ 0.55
Term of stock option issued		5 years
Term of warrants		3 years
Number of brokers warrants exercisable		3,937.50
Number of warrants issued		225,000
Exercise price of warrants		$ 0.80